

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Appl. No. : 10/066,273
Filed : February 1, 2002

REMARKS

Applicants have amended Claim 40 to delete reference to Figure 4 and to clarify that the antibody specifically binds to the polypeptide of SEQ ID NO: 9. Applicants maintain that the amendments add no new matter and are fully supported by the specification as originally filed. Accordingly, Claims 40-44 are presented for examination. Applicants respond below to the specific rejections raised by the PTO in the Office Action mailed April 28, 2004. For the reasons set forth below, Applicants respectfully traverse.

Use of Trademarks in the Specification

Paragraphs in the specification containing non-capitalized trademarks have been amended. Accordingly, the trademarks in the specification are now both capitalized and accompanied by the appropriate generic terminology. These amendments to the specification do not add new matter and Applicants respectfully submit that the use of trademarks in the specification is in accordance with MPEP §608.01(v).

Rejection under 35 U.S.C. §101 – Utility

The PTO has rejected Claims 40-45 under 35 U.S.C. § 101 as lacking patentable utility. More specifically, the PTO alleges that the invention lacks any apparent or disclosed, specific and substantial, credible utility. Applicants respectfully disagree.

Utility – Legal Standard

According to the Utility Examination Guidelines (“Utility Guidelines”), 66 Fed. Reg. 1092 (2001) an invention complies with the utility requirement of 35 U.S.C. § 101, if it has at least one asserted “specific, substantial, and credible utility” or a “well-established utility.”

Under the Utility Guidelines, a utility is “specific” when it is particular to the subject matter claimed. For example, it is generally not enough to state that a nucleic acid is useful as a diagnostic without also identifying the condition that is to be diagnosed.

Appl. No. : 10/066,273
Filed : February 1, 2002

The requirement of “substantial utility” defines a “real world” use, and derives from the Supreme Court’s holding in *Brenner v. Manson*, 383 U.S. 519, 534 (1966) stating that “The basic *quid pro quo* contemplated by the Constitution and the Congress for granting a patent monopoly is the benefit derived by the public from an invention with substantial utility.” In explaining the “substantial utility” standard, M.P.E.P. §2107.01 cautions, however, that Office personnel must be careful not to interpret the phrase “immediate benefit to the public” or similar formulations used in certain court decisions to mean that products or services based on the claimed invention must be “currently available” to the public in order to satisfy the utility requirement. “Rather, *any reasonable use that an applicant has identified for the invention that can be viewed as providing a public benefit should be accepted as sufficient*, at least with regard to defining a ‘substantial’ utility.” (M.P.E.P. § 2107.01, *emphasis added*.)

Indeed, the Guidelines for Examination of Applications for Compliance With the Utility Requirement, set forth in M.P.E.P. §2107 II(B)(1) gives the following instruction to patent examiners: “If the applicant has asserted that the claimed invention is useful for any particular practical purpose ... and the assertion would be considered credible by a person of ordinary skill in the art, do not impose a rejection based on lack of utility.”

Utility – Evidentiary Standard

An Applicant's assertion of utility creates a presumption of utility that will be sufficient to satisfy the utility requirement of 35 U.S.C. § 101, “unless there is a reason for one skilled in the art to question the objective truth of the statement of utility or its scope.” *In re Langer*, 503 F.2d 1380, 1391, 183 USPQ 288, 297 (CCPA 1974). See, also *In re Jolles*, 628 F.2d 1322, 206 USPQ 885 (CCPA 1980); *In re Irons*, 340 F.2d 974, 144 USPQ 351 (1965); *In re Sichert*, 566 F.2d 1154, 1159, 196 USPQ 209, 212-13 (CCPA 1977).

Compliance with 35 U.S.C. § 101 is a question of fact. *Raytheon v. Roper*, 724 F.2d 951, 956, 220 USPQ 592, 596 (Fed. Cir. 1983) cert. denied, 469 US 835 (1984). The evidentiary standard to be used throughout *ex parte* examination in setting forth a rejection is a preponderance of the totality of the evidence under consideration. *In re Oetiker*, 977 F.2d 1443,

Appl. No. : 10/066,273
Filed : February 1, 2002

1445, 24 USPQ2d 1443, 1444 (Fed. Cir. 1992). Thus, to overcome the presumption of truth that an assertion of utility by the applicant enjoys, the PTO must establish that it is more likely than not that one of ordinary skill in the art would doubt the truth of the statement of utility. Only after the PTO has made a proper *prima facie* showing of lack of utility does the burden of rebuttal shift to the applicant. The issue will then be decided on the totality of evidence.

Specific, Substantial, and Credible Utility

The PTO asserts that the invention allegedly lacks substantial utility because the claims are drawn to antibodies that bind to polypeptides (PRO444) having, as of yet, an undetermined function or biological significance. More specifically, the PTO argues that evidence in the specification that PRO444 polypeptides are capable of inducing the expression of c-fos in pericyte cells, is not sufficient to adequately support the asserted utilities of diagnosing and treating tumors, and stimulating angiogenesis under 35 U.S.C. §101.

Applicants respectfully disagree. The claimed antibodies bind to PRO444 polypeptides and are thus useful for the affinity purification of these polypeptides from recombinant cell cultures or natural sources. See specification page 99, lines 1-2. While 35 U.S.C §101 only requires that one specific, substantial, and credible utility be either asserted or well established, the specification provides at least three asserted utilities for PRO444 polypeptides and the claimed antibodies. The first two disclosed utilities are that PRO444 polypeptides induce the expression of c-fos in pericyte cells, and therefore, are useful not only as diagnostic markers for pericyte associated tumors, but also for giving rise to antagonists that are useful for the therapeutic treatment of pericyte associated tumors. Specific antagonists include the claimed antibodies, for example. Thus the first two disclosed utilities relate to pericyte tumor diagnosis and treatment. Furthermore, as c-fos expression induces angiogenesis, the third asserted utility is that PRO444 polypeptides are useful in stimulating angiogenesis. Inducing angiogenesis could be beneficial for patients in need of wound healing, for example. Accordingly, in addition to being useful in treating tumors, the claimed antibodies also have utility in purifying and detecting useful PRO444 polypeptides.

Appl. No. : 10/066,273
Filed : February 1, 2002

As the assertion of a utility creates a presumption of utility sufficient to satisfy 35 U.S.C. §101, the burden is on the Examiner to prove that it is more likely than not that a skilled artisan would doubt the truth of the statement of utility. *In re Langer*, 503 F.2d 1380, 1391, 183 USPQ 288, 297 (CCPA 1974). See, also *In re Jolles*, 628 F.2d 1322, 206 USPQ 885 (CCPA 1980); *In re Irons*, 340 F.2d 974, 144 USPQ 351 (1965); *In re Sichert*, 566 F.2d 1154, 1159, 196 USPQ 209, 212-13 (CCPA 1977).

The PTO has attempted to rebut the presumption of utility by relying on three references to support its position that c-fos expression represents a general cellular response to a variety of stimuli. According to these cited references, alleged stimuli capable of inducing c-fos include growth factors, cytokines, serum, UV-light, neurotropic factors, neurotransmitters, depolarizing agents, and ion channel activating agents. The PTO concludes that because "c-fos appears to be a non-specific first line of cellular response...one skilled in the art would readily conclude that activation of c-fos could not support the assertion that PRO444 polypeptide could be specifically used 'as diagnostic marker[s] for particular types of pericyte-associated tumors'."

Applicants respectfully disagree with the PTO's position. The PTO appears to be asserting that because numerous stimuli are capable of inducing c-fos, the expression of c-fos is a non-specific first line of cellular response, and therefore not a sufficiently asserted utility. Contrary to the PTO's stated position, the important issue to consider is not whether numerous stimuli are capable of inducing the expression of c-fos, but rather, whether the ability to induce c-fos, by itself, is a substantial, specific and credible utility sufficient to satisfy the requirements of 35 U.S.C. §101.

In addressing the above-stated issue, Applicants respectfully submit that polypeptides capable of inducing c-fos expression, more specifically the polypeptides that the claimed antibodies bind to, have substantial, specific, and credible use. In particular, the c-fos gene is a well known proto-oncogene that is a major target for signal transduction pathways involved in the regulation of cell growth, differentiation, and transformation. (See: Saez *et al.*, "c-fos is required for malignant progression of skin tumors" *Cell*, 82(5) 721-32, Sept. 8, 1995 submitted herewith). In a study that examined whether c-fos deficient mice were capable of developing

Appl. No. : 10/066,273
Filed : February 1, 2002

cancer, it was shown that mice containing a c-fos knockout gene failed to develop malignant tumors, whereas wild-type mice (c-fos positive) did. (*Id.*) The authors of the study concluded that c-fos deficient cells appear to have an intrinsic defect that hinders tumorigenesis. (*Id.*)

In light of the above study, one skilled in the art would reasonably conclude that the claimed antibodies bind to polypeptides having real world utility. More particularly, these polypeptides (PRO444) induce the expression of a transcription factor (c-fos) described as critical in tumorigenesis. Thus, the presence of the claimed polypeptides in a subject's tissues or cells (*e.g.*, pericytes) would indicate that the c-fos proto-oncogene is expressing more c-fos transcription factor than normal, and it is more likely than not that the patient has a malignant tumor. Similarly, as c-fos transcription factor has been suggested to be critical in tumorigenesis, the absence of the claimed polypeptides in a subject's tissues or cells (*e.g.*, pericytes) would indicate that it is less likely than not that the patient has a malignant tumor. In light of PRO444's clear diagnostic utility, the claimed antibodies are useful in purifying and/or detecting these polypeptides in a subject suspected of having cancer.

With respect to the second asserted utility, the claimed antibodies are useful for neutralizing PRO444's functional activity. More specifically, a skilled artisan would reasonably conclude that a reduction in PRO444 activity would, in turn, minimize the expression of c-fos proto-oncogene, and thus could be used in a treatment regimen for a patient suffering from a malignant tumor. As stated above, c-fos has been suggested to be a critical factor in the onset of tumorigenesis. Accordingly, even if stimuli, other than PRO444 polypeptides, are capable of inducing c-fos expression in the patient, it would still be beneficial to prevent the expression of a proto-oncogene suggested to be necessary for tumorigenesis to any extent possible. Thus, the fact that other stimuli have been reported to induce c-fos, is not dispositive of the issue. In light of their ability to inhibit PRO444 activity, the claimed antibodies possess specific, substantial and credible therapeutic benefits for cancer patients.

Of course the claimed antibodies can also be used to purify PRO444 polypeptides in order to generate even more antibodies (*e.g.*, monoclonal antibodies) against PRO444. This can be done using techniques that are well known in the art. Specific techniques for generating anti-

Appl. No. : 10/066,273
Filed : February 1, 2002

PRO antibodies are described in detail in the specification. For example, pages 91-92 of the specification describe how a skilled artisan can readily generate anti-PRO444 monoclonal antibodies.

Applicants also wish to address the third asserted use of PRO444 polypeptides, which relates to their ability to induce angiogenesis, or the formation of new blood vessels. More specifically, it is well established that c-fos is capable of inducing growth factors that induce the onset of angiogenesis. (See: Marconcini *et al.*, “c-fos induced growth factor/vascular endothelial growth factor induces angiogenesis in vivo and in vitro” *Proc. Natl. Acad. Sci. U.S.A.*, 96(17): 9671-6, Aug. 17, 1999 submitted herewith). Accordingly, PRO444 polypeptides, purified using the claimed antibodies, can be administered to a patient in need of angiogenesis. As discussed in the specification, angiogenesis is useful in facilitating wound healing in a patient. More specifically, the generation of new vessels provides nutrients to the wound site, promotes granulation tissue formation, and facilitates the clearance of debris. Again, it is important to reiterate that PRO444 polypeptides are helpful in stimulating angiogenesis, regardless of whether or not other compounds have been reported to stimulate angiogenesis or c-fos induction.

The PTO also argued that the disclosed utilities were not specific enough because the specification fails to identify “a particular type of tumor that the PRO444 is specifically associated with.” However, this is not the standard for determining whether a “specific” utility has been asserted. Applicants statements regarding PRO444 polypeptides and antibodies usefulness in treating and diagnosing pericyte-associated tumors, are sufficiently specific to satisfy the requirements of 35 U.S.C. §101. Cancer is an extensively studied and well known physiological condition that is readily characterized by its numerous specific properties. Applicants are not required to recite exact tumor types (e.g., breast, brain) that the claimed inventions can treat or diagnose in order to comply with the PTO’s utility requirements. There are numerous general treatments (e.g., radiation, chemotherapy) and diagnostics available for cancer that are not limited to exact types of cancer, yet have well established specific utility. Applicants also note that stimulating angiogenesis is a sufficiently specific asserted utility of PRO444 polypeptides. For these reasons, Applicants assert that the claimed inventions have sufficiently “specific” utility.

Appl. No. : 10/066,273
Filed : February 1, 2002

Lastly, Applicants emphasize that 35 U.S.C. §101 only requires the application to have *one* asserted “specific, substantial, and credible utility” or a “well-established utility.” *See* Utility Examination Guidelines (“Utility Guidelines”), 66 Fed. Reg. 1092 (2001). Accordingly, if the Examiner finds that PRO444 polypeptides or the claimed antibodies have substantial, specific and credible utility in any of the three utilities asserted and discussed herein (*e.g.*, treating or diagnosing tumors, or stimulating angiogenesis), this rejection must be withdrawn.

Conclusion

Applicants have provided arguments and references to show that the claimed invention does have specific, substantial, and credible utility. Applicants submit that one of ordinary skill in the art would have no legitimate basis to doubt the credibility of the statements made in the specification and herein that set forth the expressly stated utilities of the claimed antibodies and PRO444 polypeptides.

Thus, given the totality of the evidence provided, Applicants submit that they have established a specific and substantial, credible utility for the claimed antibodies and PRO444 polypeptides either as diagnostic or therapeutic agents associated with cancer, or for stimulating angiogenesis. According to the PTO Utility Examination Guidelines (2001), irrefutable proof of a claimed utility is not required. Rather, a specific and substantial credible utility requires only a “reasonable” confirmation of a real world context of use. Applicants submit that they have established that it is more likely than not that one of skill in the art would reasonably accept the utility for the claimed antibodies and PRO444 polypeptides set forth in the specification. In view of the above, Applicants respectfully request that the PTO reconsider and withdraw the utility rejection under 35 U.S.C. §101.

Rejection under 35 U.S.C. §112 – Enablement

The PTO also rejected Claims 40-45 under 35 U.S.C. § 112, first paragraph, as containing subject matter which was allegedly not described in the specification in such a way as to enable one skilled in the art to make and/or use the invention. Specifically, the PTO tied this rejection to the 35 U.S.C. §101 rejection, set forth above, and argued that since the claimed invention is

Appl. No. : 10/066,273
Filed : February 1, 2002

not supported by either a clear asserted utility or a well established utility, one skilled in the art clearly would not know how to use the claimed invention.

The Applicants respectfully assert that the arguments set forth in detail above make clear that the claimed antibodies and PRO444 polypeptides are useful in diagnosing and treating cancer, and inducing angiogenesis in a subject in need. In light of PRO444's demonstrated ability to stimulate c-fos expression, each of the asserted utilities is specific, substantial, and credible. Accordingly, the specification teaches a sufficient utility such that a skilled artisan could make and use the claimed inventions without undue experimentation. In view of the above, Applicants respectfully request that the PTO reconsider and withdraw the enablement rejection under 35 U.S.C. § 112, first paragraph.

Rejection under 35 U.S.C. §112 – Definiteness

Claim 45 was rejected under 35 U.S.C §112, second paragraph, as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. More specifically, Claim 45 was alleged to be vague and indefinite for the recitation of the term “specifically binds.” While Claim 45 has been cancelled, Claim 40 now recites this term.

Applicants respectfully disagree with the Examiner, as this term has a well-established meaning in the field of immunotherapy. More specifically, those with skill in the art would readily recognize that the term “specifically binds,” as recited in the claims, relates to antibodies that specifically bind to one particular polypeptide, defined by its amino acid sequence. Accordingly, the term “specifically binds,” as used in Claim 45, refers to antibodies that bind to polypeptides having the amino acid sequence of SEQ ID NO: 9 and not substantially to any other polypeptides.

It is also noted that claims reciting an antibody that “specifically binds” to a particular polypeptide, having a specific amino acid sequence, have been allowed in other U.S. patents. *See e.g.*, Claim 12, U.S. Patent No. 6,326,482, issued to Stewart et al., December 4, 2001. Accordingly, Applicants respectfully request the PTO to reconsider and withdraw this rejection.

Appl. No. : 10/066,273
Filed : February 1, 2002

CONCLUSION


In view of the above, Applicants respectfully maintain that the claims are patentable and request that they be passed to issue. Applicants invite the Examiner to call the undersigned if any remaining issues may be resolved by telephone.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: July 27, 2004

By: 
AnneMarie Kaiser
Registration No. 37,649
Attorney of Record
Customer No. 30,313
(619) 235-8550

c-fos Is Required for Malignant Progression of Skin Tumors

Enrique Saez,* Susan E. Rutberg,†
Elisabetta Mueller,* Heather Oppenheim,*
Jennifer Smoluk,* Stuart H. Yuspa,†
and Bruce M. Spiegelman*

*Dana-Farber Cancer Institute
and Department of Cell Biology
Harvard Medical School
Boston, Massachusetts 02115

†Laboratory of Cellular Carcinogenesis
and Tumor Promotion
National Cancer Institute
Bethesda, Maryland 20892

Summary

The proto-oncogene *c-fos* is a major nuclear target for signal transduction pathways involved in the regulation of cell growth, differentiation, and transformation. Using the multistep skin carcinogenesis model, we have directly tested the ability of *c-fos*-deficient mice to develop cancer. Upon treatment with a tumor promoter, *c-fos* knockout mice carrying a v-H-ras transgene were able to develop benign tumors with similar kinetics and relative incidence as wild-type animals. However, *c-fos*-deficient papillomas quickly became very dry and hyperkeratinized, taking on an elongated, horny appearance. While wild-type papillomas eventually progressed into malignant tumors, *c-fos*-deficient tumors failed to undergo malignant conversion. Experiments in which v-H-ras-expressing keratinocytes were grafted onto nude mice suggest that *c-fos*-deficient cells have an intrinsic defect that hinders tumorigenesis. These results demonstrate that a member of the AP-1 family of transcription factors is required for the development of a malignant tumor.

Introduction

Advances in molecular biology have served to outline the multiple genetic components that are involved in the development of cancer. It is now well established that for a cell to grow aggressively within the context of the organism, proto-oncogenes must be mutated to become active growth inducers, tumor suppressor genes must be functionally lost, and the cell must be released from its own self-destruction program. Many of the important molecules in cancer development are proteins that function outside the nucleus of the cell, either assessing changes in the extracellular environment or relaying messages from sensor proteins to the control center of the cell. Because mitogens, growth factors, and tumor promoters regularly use these signal transduction pathways, mutations in genes implicated in either signal recognition or propagation can induce the cell to behave inappropriately. Upon reaching the nucleus, signals from these proteins must

communicate with transcription factors to elicit the changes in gene expression that can allow the cell to react to its new environment.

One class of transcription factors that it is thought to serve as the nuclear target of many oncogenic signal transduction pathways is the activator protein 1 (AP-1) family (reviewed by Ransone and Verma, 1990; Angel and Karin, 1991). This multigene group includes members of the Fos (*c-fos*, *fosB*, *fra-1*, and *fra-2*) and Jun (*c-jun*, *junB*, and *junD*) families. Members of the Fos family form heterodimers with Jun proteins and regulate transcription by binding DNA at AP-1 sites. These *cis*-acting regulatory elements are found in a variety of genes involved in cell proliferation, differentiation, and tumorigenesis. Oncogenic activation of several signal transduction pathways can result in increased AP-1 activity. For example, tumorigenic mutations in the proto-oncogene H-ras activate a family of mitogen-activated protein (MAP) kinases (JNKs/SAPKs) that phosphorylate Jun to augment its transactivation potential (Pulverer et al., 1991; Binetruy et al., 1991). Recently, an analogous class of Ras-responsive intracellular kinases has been described that seems to regulate Fos activity (Deng and Karin, 1994). It is unclear from these in vitro studies, however, how elevated AP-1-dependent gene expression can contribute to cancer development in vivo.

A clue to the significance of AP-1 activity for cell transformation can be found in the history of *fos* and *jun*, as both genes were initially described as the transforming principles of oncogenic retroviruses (Curran et al., 1982; Maki et al., 1987). Later studies using transgenic mice showed that stable expression of *c-fos* led to a dysregulation of bone growth eventually resulting in osteosarcomas and chondrosarcomas (Ruther et al., 1987, 1989). Transgenic mice expressing an oncogenic form of *jun* developed fibrosarcomas at sites of wound healing (Schuh et al., 1990). These observations indicated that aberrant expression of AP-1 genes could affect mitogenic control and promote neoplastic transformation of specific tissues.

Through the use of embryonic stem cell gene targeting technology, null mouse mutations of *c-fos* and *c-jun* have recently been generated (Johnson et al., 1992, 1993; Wang et al., 1992; Hilberg et al., 1993). While the *c-jun* knockout mutation is embryonic lethal, the *c-fos* null mouse is viable, though it displays a variety of tissue-specific anomalies. These defects include a severe form of osteopetrosis, a mild lymphopenia, delayed gametogenesis, and some behavioral abnormalities. In spite of these deficiencies, the availability of these mutant mice has allowed us to use them as tools to study the role of *c-fos* in cancer development in vivo. Our intention was to examine the unfolding of the neoplastic process in the absence of a critical component of the AP-1 family.

To address the relevance of *c-fos* for cancer development, we have used the classical model of multistep mouse skin carcinogenesis (reviewed by DiGiovanni, 1992; Hennings et al., 1993; Yuspa, 1994). Tumor devel-

opment in mouse skin can be divided into three steps: initiation, promotion, and progression. Initiation is an irreversible step that experimentally can be brought about by the application of a single dose of a mutagen (e.g., 2,5-dimethoxybenzaldehyde [DMBA]). Initiated cells can lie dormant until they are induced to proliferate, either by repeated treatments with a tumor promoter (e.g., 12-O-tetradecanoylphorbol-13-acetate [TPA]) or by a natural promoting stimulus such as wounding. During promotion, initiated cells are thought to have a growth advantage, and the tissue hyperplasia eventually results in a visible benign clonal outgrowth, a papilloma. Over time, papillomas can accumulate additional genetic mutations and progress into a malignant tumor, a squamous cell carcinoma. Carcinomas can undergo a further epithelial-mesenchymal transition to give rise to highly invasive spindle cell tumors (Klein-Szanto et al., 1989; Buchmann et al., 1991).

In this study, we have found that while *c-fos* does not seem to be necessary for normal epidermal differentiation or for the early proliferative steps of skin tumor formation, it is required for malignant tumor conversion. These results offer clear genetic evidence that an AP-1 factor is indispensable for the development of certain cancers.

Results

c-fos-Deficient Keratinocytes Form a Normal Epidermis

The skin is one of the few adult tissues in which *c-fos* expression has been reported to be constitutive (Fisher et al., 1991; Smeyne et al., 1992). Coupled with the observation that functional AP-1 sites can be found in a variety of genes associated with epidermal development, this finding raised the possibility that the skin of *c-fos* null mice could display an aberrant pattern of differentiation. To uncover any intrinsic abnormalities in unperturbed *c-fos*-deficient skin, we stained newborn epidermis with markers for specific stages of keratinocyte differentiation. Figure 1A shows double-labeled immunofluorescence staining for three markers: keratin 14 (K14), expressed in proliferating basal keratinocytes; keratin 1 (K1), induced in the differentiating spinous cells; and loricrin, a component of the cornified envelope expressed in the terminally differentiated cells of the granular layer. Comparison of the staining patterns for these and other epidermal differentiation markers failed to reveal any differences among mice of varying *c-fos* genotype. Histological examination of newborn *c-fos*-deficient skin showed that no obvious differ-




Figure 1. Analysis of Wild-Type and *c-fos*-Deficient Epidermis

(A) Indirect immunofluorescence staining of epidermal differentiation markers in newborn epidermis. In the top panels, K14 staining is shown in green and K1 in red. Areas of overlap appear yellow. The bottom panels show K14 in green and loricrin in red. Again, areas of common staining are yellow. Magnification, 204x.

(B) Hematoxylin and eosin staining of wild-type and *c-fos*-deficient newborn skin. Magnification, 163x.

ences exist in epidermal organization or cellularity (Figure 1B). Analogous results were obtained with thinner adult skin. Furthermore, when newborn mice were injected with bromodeoxyuridine to identify epidermal cells undergoing DNA replication, the number of proliferating cells was found to be similar in both genotypes (data not shown). These observations allowed us to conclude that, on the basis of keratinocyte growth rate or pattern of differentiation-dependent gene expression, the skin of *c-fos*-deficient mice is indistinguishable from that of wild-type mice.

c-fos Is Not Required for the Early Stages of Skin Carcinogenesis

To induce tumor formation in the skin of mice, we used a modified version of a traditional DMBA/TPA tumor induction protocol. Instead of using a chemical initiator, *c-fos* mutant mice were bred with a transgenic strain (TG.AC) carrying a v-H-ras transgene that can act as a classical initiation event (Leder et al., 1990). The existence of this transgenic strain enabled us to avoid the use of initiators that would have introduced undefined genetic mutations, potentially complicating the interpretation of the results. Even though the transgene is under the control of an embryonic globin promoter and thus is not normally active in the skin, expression of the transgene is induced in epidermal cells when they are prompted to proliferate either by application of tumor promoters or by a natural stimulus such as hair plucking (Hansen and Tennant, 1994a, 1994b). Mice carrying the TG.AC transgene are very sensitive to a variety of tumor promoters; they rapidly develop large numbers of papillomas (Spalding et al., 1993).

Mice homozygous for the TG.AC transgene were mated with mice heterozygous for the *c-fos* null mutation. Offspring carrying both mutations were identified and interbred to generate mice of all possible genotypes. The dorsal epidermis of these mice was then treated with the tumor promoter TPA twice a week for 5 weeks, according to standard promotion protocols for the TG.AC strain. Treated mice were monitored biweekly for the appearance of papillomas. As can be discerned from Figure 2, *c-fos*-deficient mice were able to develop papillomas, and they did so with equivalent kinetics to those of their wild-type and heterozygous littermates. Furthermore, the time to appearance of the first tumor and the number of papillomas per mouse were indistinguishable among genotypes. Because papillomas are very heterogeneous and often tend to coalesce with other papillomas, size comparisons are difficult. Nevertheless, no obvious differences in tumor size could be observed among mice of differing genotypes.

Table 1 summarizes benign tumor incidence rates. A small minority of v-H-ras transgenic mice in each group proved to be resistant to TPA treatment. This resistance did not correlate with *c-fos* genotype and has previously been described for inbred FvB/N TG.AC mice. Two conclusions can be drawn from the data in Table 1 regarding the role of *c-fos* in the early steps of mouse skin carcinogenesis. First, the absence of *c-fos* cannot act as an initiat-




Figure 2. Initial Kinetics of Papilloma Appearance

Number of papilloma-bearing mice as a percentage of those treated with tumor promoter: wild-type mice (closed circles; $n = 19$), heterozygous mice (open squares; $n = 35$), and *c-fos* null mice (open circles; $n = 29$).

Second, since *c-fos*-deficient mice bearing the v-H-ras transgene developed papillomas in a normal manner, it is clear that in this model of carcinogenesis, this proto-oncogene is not necessary for promotion.

c-fos-Deficient Papillomas Evolve into Horny, Elongated Tumors Characterized by Massive Hyperkeratinization

Although *c-fos*-deficient papillomas initially displayed an identical external appearance to wild-type tumors, a striking change in morphology was noticed soon after the end of promotion. Within 4 weeks after TPA treatment was completed, the papillomas on all *c-fos* null mice started to become very dry, elongated, and hyperkeratinized. This change in morphology was very apparent as the study advanced. Though some papilloma regression was observed in mice of all genotypes, the papillomas that persisted on wild-type and heterozygous mice remained vigorous and well vascularized. In contrast, mutant papillomas became desiccated and extremely hyperkeratinized and showed little external vascularization. Figure 3A shows a comparison of wild-type and *c-fos* null papillomas soon after the end of promotion. While wild-type papillomas retained a similar morphology until the end of the study, *c-fos*-deficient tumors acquired a rather horny appearance: they evolved into severely keratinized, grotesque projections. Examples of these older *c-fos*-deficient tumors are shown in Figure 3C. Histopathology of wild-type and mutant papillomas revealed that *c-fos*-deficient tumors indeed display a very dramatic hyperkeratinization, showing a remarkable increase in the terminally differentiated stratum corneum (Figure 4). In addition, *c-fos*-deficient papillomas seemed to present an abrupt transition between the basal layer and the stratum corneum,

Table 1. Benign Tumor Incidence Rates

Genotype	Treatment	Papillomas	Incidence (%)	Papillomas per Mouse	Time to First Tumor
<i>c-fos</i> wild-type transgenic v-H-ras	TPA	17 of 19	90	26 ± 14.4	33.4 ± 7.2
	Acetone	0 of 4	0		
<i>c-fos</i> heterozygous transgenic v-H-ras	TPA	30 of 35	86	22 ± 15.7	34.8 ± 8.9
	Acetone	0 of 5	0		
<i>c-fos</i> -deficient transgenic v-H-ras	TPA	26 of 29	90	23 ± 14.3	32.0 ± 7.7
	Acetone	0 of 6	0		
<i>c-fos</i> wild type	TPA	0 of 9	0		
<i>c-fos</i> heterozygous	TPA	0 of 13	0		
<i>c-fos</i> deficient	TPA	0 of 6	0		

At 12 weeks of age, all mice were shaved and promotion treatment was started either with TPA or with solvent alone (acetone). Mice were monitored biweekly for the appearance of tumors. Papillomas per mouse and time to first tumor statistics are given as mean ± SD.

the *c-fos* null mutation appeared identical to wild-type papillomas: their morphology did not change, and they did not present an abnormal epidermal architecture.

To investigate whether these hyperkeratinized *c-fos*-deficient tumors showed an abnormal rate of regression, we compared the average number of papillomas per mouse at 9 weeks and at 23 weeks. Since TPA treatment was discontinued at the end of week 5, the majority of regressing papillomas should have disappeared by week 23. In wild-type mice, the mean number of papillomas per mouse decreased from 26 at week 9 to 10.5 at week 23 (a 60% reduction). Heterozygous mice showed a very similar decline, from 22.1 tumors per mouse at week 9 to 8.9 at week 23 (a 60% decrease). The mean number of papillomas per mouse in *c-fos*-deficient animals decreased from 23 at week 9 to 4.7 at week 23 (an 80% reduction). These data show that *c-fos* is not required for the persistence of papillomas. Whether papilloma regression rates are significantly affected by the *c-fos* null mutation is an issue that will require more study.

Papillomas Lacking *c-fos* Fail to Undergo Malignant Conversion

Wild-type mice began to develop malignant skin tumors around week 20, although most cases of malignant progression were noticed between weeks 25 and 30. Malignant lesions first appeared as ulcerated areas within a papilloma that grew rapidly. These malignant tumors were identified histologically as either squamous cell carcinomas or, more frequently, spindle cell tumors, in agreement with what has been described for the TG.AC strain (French et al., 1994). By the end of the study (week 45), malignant progression had been observed in 4 of 7 (57%) surviving wild-type mice and in 7 of 17 (41%) heterozygous mice (Table 2). In contrast, no malignant skin tumors had been detected in 13 remaining *c-fos* null mice. A detailed pathological examination of all remaining *c-fos*-deficient papillomas at the end of the study failed to find any evidence of microscopic malignant progression. The decrease in the number of mice that were available at the later timepoint to assess progression is a reflection of the fact that the v-H-ras TG.AC transgene induces a variety of other tumors

(e.g., hematopoietic malignancies) that necessitate the sacrifice of the affected animal. Nevertheless, the difference in progression rates of tumors with or without *c-fos* (57% and 41% versus 0%) is statistically significant ($p < 0.0001$) and allows us to conclude that *c-fos* is required for malignant progression of experimentally induced skin tumors. Wild-type and *c-fos*-deficient papillomas expressed similar levels of transgenic v-H-ras 1 month after the end of tumor promoter treatment (Figure 5B). Hence, the inability of *c-fos*-deficient papillomas to become malignant is not due to a reduced level of oncogenic H-ras expression. These final progression figures do not exclude the possibility of a heterozygous effect, although the finding that heterozygous papillomas behave like wild-type papillomas by all criteria examined argues against it.

Alterations in Gene Expression in *c-fos* Null Papillomas

To examine whether the lack of malignant progression of *c-fos*-deficient tumors correlated with specific changes in gene expression, we isolated RNA from pools of papillomas from wild-type and *c-fos*-deficient mice. Each pool consisted of five to six tumors taken 1 month after the end of TPA treatment. These RNAs were used to measure the degree of expression of certain AP-1-regulated genes in the papillomas. The genes encoding the tumor metalloproteases stromelysin and type I collagenase were of particular interest because studies using *c-fos*-deficient fibroblasts had shown that *c-fos* is required for the induction of these genes in response to mitogenic stimulation (Hu et al., 1994). In addition, enhanced expression of these tumor metalloproteases has been associated with the progression of benign, encapsulated papillomas to malignant, invasive tumors (Matrisian et al., 1986; Liotta and Stetler-Stevenson, 1990). While the stromelysin and type I collagenase mRNAs were detectable in the pools of wild-type tumors, they were virtually absent in RNA pools from *c-fos*-deficient papillomas (Figures 5A and 5B). The apparent lack of external vascularity of mutant tumors also prompted us to assess the level of expression of angiogenic factors in the papillomas. Of special interest was the pattern of expression of vascular endothelial growth






Figure 3. External Appearance of Papillomas

(A) A wild-type mouse (left) and a *c-fos*-deficient littermate (right) are shown 3 weeks after the end of promotion.

(B) *c-fos* null mouse 9 weeks after the end of promotion (14 weeks from the start of treatment); note the change in morphology that is now obvious in all papillomas.

(C) Wild-type and *c-fos*-deficient tumors 4 months after the conclusion of TPA treatment. The black mouse is the same mouse as that shown in (B). Notice the absence of external vascularity in the large tumors of the brown *c-fos*-deficient mouse. Color coat segregates independently of both the TG.AC transgene and the *c-fos* null mutation.

factor (VEGF), for this protein may be the prime regulator of normal and tumor angiogenesis (Klagsbrun and Soker, 1993). The VEGF gene was expressed in *c-fos*-deficient tumors, but the levels of VEGF mRNA measured in mutant papillomas were 5- to 10-fold lower than those found in RNA pools derived from wild-type papillomas (Figure 5C).

The changes in keratin gene expression that take place during a protocol of skin carcinogenesis are well established and can often serve as markers of the degree of tumor progression. For example, papillomas with a high risk for malignant conversion frequently replace K1 expression with that of K13, a keratin whose expression is

normally restricted to internal epithelia (Nischt et al., 1988; Gimenez-Conti et al., 1990). Regions of premalignant papillomas that express K13 do not normally express K1. To monitor keratin gene expression in *c-fos*-deficient papillomas, we stained serial sections of tumors with antibodies prepared against an array of keratins. Surprisingly, K13 expression was ubiquitous in the suprabasal layers of *c-fos*-deficient papillomas. More significantly, though, while K1 and K13 expression was mutually exclusive in wild-type papillomas, these two keratins were invariably coexpressed in the same cells in the mutant papillomas. K1 expression persisted in spite of K13 induction in all




Figure 4. Histology of Papillomas

Hematoxylin and eosin-stained sections of 2-month-old tumors (3 weeks after TPA removal). The top panels show a wild-type and a *c-fos*-deficient tumor at the same level of magnification (13 \times). Note the striking hyperkeratinization of the *fos*-less papilloma and the abrupt transition between the basal (b) and the cornified layers (sc). At higher magnification (135 \times ; same for both genotypes), the contraction of the layers in the *c-fos*-deficient tumor becomes more evident.

c-fos-deficient papillomas examined (Figure 6). Since these type 1 and type 2 keratins do not normally form filament pairs, coexpression of K1 and K13 in the same cells could result in the formation of an irregular intermediate filament network that may contribute to the unusual amount of cornification displayed by mutant papillomas. In contrast with wild-type cornified envelopes, which disassociate when tumors are boiled, large clumps of tightly connected *c-fos*-deficient envelopes endured even after the mutant papillomas were boiled for 5 hr in 2% SDS (data not shown). The considerable durability of *c-fos*-deficient cornified envelopes may reflect interesting underlying biochemical differences, such as covalent modifications in the structure of the envelopes.

c-fos-Deficient Keratinocytes Expressing v-H-ras Do Not Form Tumors When Grafted onto Nude Mice

The development of a malignant neoplasm is a process that involves an intense interaction between tumor cells and normal neighboring cells (reviewed by Pawletz and Boxberger, 1994). The inability of *c-fos*-deficient papillomas to progress into malignant tumors could be due to an intrinsic defect in the v-H-ras-expressing keratinocytes that form the epidermal component of the papillomas. Al-

ternatively, it is possible that malignant tumors do not arise in these animals because the nontransformed *c-fos*-deficient cells neighboring the neoplastic keratinocytes do not provide an environment that is conducive for malignant




Figure 5. Expression of *c-fos*-Regulated Genes in Papillomas

RNA was prepared from papillomas 1 month after the end of promotion and analyzed by Northern blot. Each lane contains total RNA from a pool of six to eight tumors. Probes are as indicated on each panel. Blots were stripped and reprobed with ribosomal-associated protein 36B4 as a control for loading.

Table 2. Incidence of Malignant Tumors

Genotype	Malignant Tumors	Percent Affected
<i>c-fos</i> wild-type transgenic v-H-ras	4 of 7	57
<i>c-fos</i> heterozygous transgenic v-H-ras	7 of 17	41
<i>c-fos</i> deficient transgenic v-H-ras	0 of 13	0

Mice were monitored weekly during 45 weeks for the appearance of malignancies. At the end of that time, all mice were sacrificed, and any remaining tumors were harvested for pathological analysis. Individual mice were sacrificed after the first malignant tumor was detected.




Figure 6. Aberrant Keratin Gene Expression in *c-fos*-Deficient Papillomas

Serial sections of tumors (obtained 2.5 months after the start of the study) were stained with antibodies against K1 (bottom) and K13 (top) and photographed at the same magnification (32 \times). Note the coexpression of K1 and K13 in *c-fos*-deficient tumors.

growth. To establish whether *c-fos*-deficient keratinocytes display a cell-autonomous defect that prevents them from giving rise to malignant tumors, we tested the ability of *v-H-ras*-expressing mutant keratinocytes to form tumors when grafted onto the back of wild-type hosts (Roop et al., 1986). Primary keratinocytes derived from *c-fos*-deficient, heterozygous, and wild-type mice were infected with a helper-free retrovirus, a variant Harvey murine sarcoma virus (Ha-MSV), expressing an oncogenic form of H-ras (Roop et al., 1986), were mixed with wild-type dermal fibroblasts, and were grafted onto the back of athymic nude mice. Grafted Ha-MSV-infected wild-type keratinocytes gave rise to large papillomas. In contrast, grafts of infected *c-fos*-deficient keratinocytes did not produce significant tumors. Rather, *v-H-ras*-expressing cells lacking *c-fos* generated a normal epidermis that was hyperplastic in some cases. Interestingly, grafts of keratinocytes heterozygous for the *c-fos* null mutation gave rise to small tumors of variable size that on average were approximately 35% the size of their wild-type counterparts. While there was some variation in absolute tumor volume values, the same trend was observed in three independent experiments: *v-H-ras*-expressing keratinocytes homozygous for the *c-fos* null mutation failed to produce tumors ($n = 8$), heterozygous cells generated small, fragmented papillomas ($n = 12$), and wild-type keratinocytes gave rise to large tumors ($n = 14$). Mice from a representative experiment are shown in Figure 7A. The presence of black pigment in mice with grafts of *c-fos*-deficient keratinocytes indicates that the graft was successful. Figure 7B displays the evolution of tumor volume as a function of time for that same experiment. Mice with *c-fos*-deficient grafts failed to develop tumors, even when monitored for 3 months (6 weeks beyond the normal observation period). Since tumor formation in this system is dependent upon oncogenic H-ras expression, the levels of mutant Ras protein in keratinocytes used for grafting were examined. All Ha-MSV-

equivalent levels of exogenous Ras in vitro as well as in vivo (data not shown). The growth rate in vitro of all *v-H-ras*-expressing keratinocytes was similar, regardless of *c-fos* genotype (data not shown). Furthermore, implanted *c-fos* null keratinocytes coinfecting with Ha-MSV and a *v-fos* retrovirus generated dysplastic tumors indistinguishable from those produced by similarly infected wild-type cells, confirming that a *fos*-dependent function is responsible for the deficiency in tumor formation of mutant cells (data not shown). These transplantation experiments illustrate that *v-H-ras*-expressing keratinocytes derived from *c-fos* null animals appear to have a cell-autonomous defect that hampers tumorigenesis.

Discussion

Tumorigenesis is a complex process that requires alterations in many genes involved in the regulation of cell growth. Many of these genes function outside of the nucleus of the cell and must ultimately exert their effects by communicating with transcription factors. The AP-1 family is believed to be one of the nuclear targets of several signal transduction pathways, in particular the Ras-MAP kinase pathway (reviewed by Hill and Treisman, 1995). Because these pathways are frequently dysregulated by activated oncogenes, it is of considerable interest to determine whether AP-1 factors are actually necessary for cancer development. We have used the well-characterized model of multistep mouse skin carcinogenesis to examine the unfolding of the neoplastic process in the absence of *c-fos*, an important member of the AP-1 family. Our results demonstrate that *c-fos* is required for the development of malignant skin tumors.

The Role of *c-fos* in Initiation and in Promotion

To test the role of *c-fos* in the various steps of skin carcinogenesis, we mated mice heterozygous for the *c-fos* null mutation with a transgenic strain carrying a *v-H-ras* transgene





Figure 7. Grafting of v-H-ras-Expressing Keratinocytes

(A) Appearance of grafts of Ha-MSV-infected keratinocytes 6 weeks after implantation. The genotype of grafted keratinocytes is shown below each picture. The presence of pigment (denoting cells of the C57BL/6J \times 129/SvJ genetic background) indicates that grafts were successful.

(B) Tumor development as a function of time for grafts of wild-type ($n = 4$), heterozygous ($n = 5$), and *c-fos*-deficient ($n = 3$) v-H-ras-expressing keratinocytes. Curves represent the average tumor volume for each group. Error bars denote SEM. Note that *c-fos*-deficient cells did not give rise to tumors.



that can substitute for a chemical initiation step. Even though mutations in *H-ras* are very common during initiation in DMBA/TPA protocols, skin tumors induced with other carcinogens frequently do not bear *H-ras* mutations (Bremner et al., 1994). This observation suggests that mutations in other unspecified genes can also serve as initiating events. To examine whether *c-fos* could be one of these unidentified genes, we treated *c-fos* null mice not carrying the v-H-ras transgene with the tumor promoter TPA. The absence of papilloma formation established that a *c-fos* null mutation cannot serve as an initiation event.

Mutant mice bearing the v-H-ras transgene were able to develop papillomas normally upon TPA treatment. That *c-fos*-deficient papillomas appeared with standard kinetics and in comparable numbers to wild-type tumors shows that, under these experimental conditions, *c-fos* is not required for benign tumor formation. Because *c-fos* is an immediate-early gene whose expression is often used as a marker of cellular proliferation, it may have been anticipated that the main contribution of *c-fos* to oncogenesis would be either to accelerate the rate of cell division or to prevent exit from the cell cycle. Clearly, this does not

seem to be the case in this study. It is possible that during promotion, TPA induces the expression of other genes that can functionally complement the absence of *c-fos*. Nonetheless, since in the vast majority of experimental carcinogenesis protocols, TPA promotion is continued for many weeks, the real relevance, if any, of *c-fos* for tumor promotion would also be concealed under those circumstances. Thus, we can conclude that, while it may be important, *c-fos* is not essential for tumor promotion brought about by TPA treatment.

Abnormalities of Epidermal Differentiation in *c-fos*-Deficient Papillomas

Although initially identical to wild-type papillomas, shortly after the end of TPA treatment, *c-fos*-deficient tumors began to manifest some clear differences. Over time, *c-fos*-deficient papillomas are characterized by a grotesque hyperkeratinization. Mutant papillomas evolve into horny projections covered by a crust of keratin that can grow as long as 2–3 cm. The development of such elongated, hyperkeratinized papillomas (with the great frequency found here) seems to be unique for a carcinogenesis proto-

col. It was surprising to find universal K13 expression in these apparently benign tumors, for K13 induction has heretofore been considered a useful diagnostic of premalignant progression. It is important to note that these *c-fos*-mediated differences in epidermal differentiation are only apparent within the context of carcinogenesis, for no differentiation abnormalities were detected in untreated *c-fos*-deficient epidermis. Hence, it is conceivable that the observed differences are contingent on the expression of a mutant H-Ras protein. It is also possible that the expression of the various members of the AP-1 family may be abnormally regulated during tumorigenesis. Given the large number of AP-1 sites that have been identified in epidermal differentiation genes, disorderly expression of other AP-1 members in the absence of *c-fos* may have profound effects. Using immunohistochemistry, we have been unable to recognize significant differences in the expression pattern of AP-1 genes in wild-type and mutant papillomas (data not shown). However, since the activity of AP-1 proteins can be regulated by reversible phosphorylation, it is possible that differences may exist in AP-1-dependent gene expression that are not reflected in an unusual pattern of AP-1 family protein expression.

The Role of *c-fos* in Papilloma Survival and Malignant Progression

In contrast with wild-type and heterozygous tumors, not a single *c-fos*-deficient papilloma progressed to malignancy by the end of the study. Several explanations can potentially account for this observation. It is well established that *c-fos* controls the expression of a variety of genes that are up-regulated during malignant progression, including those encoding the tumor metalloproteases stromelysin and type I collagenase (Kerr et al., 1988; Schonthal et al., 1988; Hennigan et al., 1994). The tumor metalloproteases are a group of secreted enzymes that can degrade the extracellular matrix, thereby facilitating tumor growth, invasion, and metastasis (reviewed by Liotta and Stetler-Stevenson, 1990). Increased metalloprotease expression has been associated with malignant progression in many models of *in vivo* cancer development (reviewed by McDonnell and Matrisian, 1990). Given that the transcripts for stromelysin and type I collagenase were undetectable in RNA obtained from pools of mutant papillomas, it is likely that a protease insufficiency may contribute to the lack of malignant behavior of *c-fos*-deficient tumors.

The sparse external vascularity displayed by *c-fos*-deficient papillomas suggests a second possible factor for the benign nature of *c-fos*-deficient tumors. At a molecular level, the formation of new blood vessels is a process remarkably similar to tumor invasion and metastasis, for angiogenesis also requires cells to traverse normal tissue boundaries and degrade the basement membrane of the tissue to be vascularized (reviewed by Liotta et al., 1991). *c-fos* could be mediating tumor angiogenesis not only through its control of the proteases that are critical for these processes, but also by modulating the expression of the growth factors that induce neovascularization, such as VEGF. Indeed, we have observed that the level of VEGF

pools of *c-fos*-deficient tumors. Finally, it is conceivable that the abnormal pattern of differentiation of *c-fos*-deficient papillomas may interfere or be incompatible with ordinary tumor progression.

Diminished expression of tumor metalloproteases and angiogenic factors may also contribute to the inability of grafted v-H-ras-expressing *c-fos*-deficient keratinocytes to generate papillomas. The development of an established graft/tumor involves complex fibroblast-keratinocyte interactions that must ultimately result in, among other things, the creation of a new blood vessel network to support the growth of the graft (Smola et al., 1993; Borchers et al., 1994). In the multistep carcinogenesis system, the requirement for angiogenesis may be less stringent, at least for the early stages of tumor development. Since tumors are induced in skin that is already vascularized, initially neoplastic cells need only to expand the existing capillary network, not to establish a completely new one. It is also possible that chemical treatment in the multistep carcinogenesis system induces the expression of genes that allow papilloma formation in the absence of *c-fos*. Many genes, including those encoding the tumor metalloproteases stromelysin and type I collagenase, are known to be expressed in response to tumor promoter stimulation; *c-fos*-deficient fibroblasts can express a limited amount of these proteases when stimulated with TPA (Krieg et al., 1988; Hu et al., 1994). The defect in tumor development observed in the grafting system could also be due to an autocrine overproduction of a growth-inhibiting molecule (e.g., transforming growth factor β) by *c-fos*-deficient cells. Alternatively, v-H-ras-expressing mutant cells may be more sensitive to constraining signals emanating from the wild-type cells that constitute the stromal component of the implant. The experimental flexibility of the skin grafting system should permit the reintroduction of proteases and angiogenic factors to test whether the cell-autonomous defect in tumorigenesis of *c-fos*-deficient keratinocytes is linked to the expression of these genes.

Although the specific details of why *c-fos*-deficient papillomas fail to progress to malignancy are yet to be elucidated, these findings might provide a molecular mechanism for the observation that treatment with retinoids and glucocorticoids can prevent malignant progression of mouse skin tumors, as well as the occurrence of secondary tumors in carcinomas of the head and neck in humans (Hong et al., 1990; Strawhecker and Pelling, 1992; De Luca et al., 1993). Both, the retinoic acid receptors and the glucocorticoid receptor are known to antagonize AP-1-dependent transcription directly (Schule et al., 1990; Kerpola et al., 1993). Thus, it is possible that the inhibitory action of these hormones on AP-1 activity is at least partially responsible for their antitumorigenic effects.

Relevance to Other Neoplastic Processes

An important question is whether these findings will be meaningful for tissues other than the epidermis. We have indirectly addressed this issue by monitoring the frequency of the spontaneous tumors induced by the v-H-ras TG.AC transgene in *c-fos*-deficient mice. We have found

nonsolid neoplasms, it appears to be critical for the development of certain solid tumors, such as odontogenic fibrosarcomas (unpublished data). Moreover, a variety of other human and rodent tumors are known to overexpress *c-fos* (e.g., Honoki et al., 1992; Urabe et al., 1992). One of these tumors is human squamous cell carcinoma of the lung (Volm et al., 1992; Wodrich and Volm, 1993). Because the development of this cancer naturally requires repeated applications of a tumor promoter (e.g., tobacco smoke), many consider this human cancer the most accurate reflection of the mouse skin model. Another clinically relevant tumor in which *c-fos* overexpression is associated with malignant progression is human breast cancer (Biunno et al., 1988; Walker and Cowl, 1991).

Our findings highlight the significance of *c-fos* for full neoplastic development. Since malignant progression is the most critical step in terms of host survival, the identification of a gene central to this process represents a promising step toward the therapeutic prevention of neoplastic disease. Furthermore, because *c-fos* is not required for the viability of the whole organism, it may represent an attractive target for pharmacological intervention.

Experimental Procedures

Animals

c-fos-deficient mice were generated as previously described (Johnson et al., 1992). Mice heterozygous for the *c-fos* null mutation (50% 129/SvJ; 50% C57BL/6J) were mated with FvB/N mice homozygous for the TG.AC transgene obtained from Charles River Laboratories. Offspring carrying both the TG.AC transgene and the *c-fos* mutation were identified and interbred. Their progeny was typed for both mutations and divided into the groups shown in Table 1. At 12 weeks of age, mice were shaved, and their dorsal epidermis was treated with either 5 μ g of TPA (Sigma) dissolved in 100 μ l of acetone or acetone alone. To normalize for their reduced size (and hence smaller dorsal surface area), *c-fos*-deficient mice received 55% of the wild-type dose of promoter. This dose of TPA resulted in a similar papilloma yield in wild-type and mutant mice (see Table 1). Treatment was applied twice a week for 5 weeks. Male mice were caged individually to prevent wound-induced tumors. All mice were examined at least once a week for a period of 45 weeks.

Histology and Immunohistochemistry

For pathological analysis, complete autopsies were performed and tissues were fixed in Optifix. Tumors were not removed from mice under observation. For fluorescent immunohistochemistry, neonatal skin was frozen in OCT (Miles Incorporated). Double-labeled indirect immunofluorescence was performed as described by Nischt et al. (1988). Antisera against mouse keratins and loricrin are characterized by Yuspa et al. (1989) and Mehrel et al. (1990).

Cell Culture and Retroviral Infections

Breeding pairs of animals heterozygous for the *c-fos* null mutation were monitored daily for the appearance of offspring. Neonatal mice were genotyped by PCR (Johnson et al., 1992). After sacrifice, animals were kept on ice until typing results became available (24 hr). The skin from selected mice was removed, and primary keratinocytes were prepared as described by Hennings et al. (1980). Dermal fibroblasts from the same *c-fos* wild-type mice used to derive keratinocytes to be grafted were cultured separately for 1 week (Yuspa et al., 1976). Primary keratinocytes were infected 3 days after plating at a multiplicity of 1 with a replication-defective variant of Ha-MSV devoid of helper virus and containing the *v-H-ras* gene (Roop et al., 1986). After 5 days, keratinocytes and fibroblasts were combined and grafted. Wild-type fibroblasts were used for grafting keratinocytes of all three genotypes. Successful Ha-MSV infection and p21 H-Ras expression were monitored by analyzing total protein extracts of infected keratinocytes by

Western blot and by immunohistochemistry on grafts, using an antibody against p21 H-Ras (Transduction Laboratories).

In Vivo Grafting

Combined cell pellets were transplanted onto 8- to 12-week-old athymic nude mice as described by Strickland et al. (1993). The volume of tumors was measured on a weekly basis, starting 2 weeks after grafting. Mice were sacrificed after 6 weeks of observation, unless otherwise noted.

Statistical Analysis

Statistical work was performed by the Division of Biostatistics at the Dana-Farber Cancer Institute. The associations between *c-fos* genotype and the incidence of epidermal tumors were analyzed with log linear models using GLIM (GLIM4, 1992 Royal Statistical Society, London), evaluating the association both assuming and not assuming and ordering to the genotype (+/+ > +/- > -/-); *p* values of <0.05 were considered significant.

Acknowledgments

Correspondence should be addressed to B. M. S. We thank Aya Leder and Raymond Tennant for advice regarding use of the TG.AC strain, Randall Johnson for suggestions regarding the care and genotyping of *c-fos* mutant mice, Andrzej Dlugosz and Ulrike Lichti for helpful discussions, Adam Glick for the *v-fos* retrovirus, Robert Cardiff and Robert Munn for histopathology and photography of tumors, Rodrigo Bravo for antibodies against AP-1 proteins, and Janet Andersen for statistical analysis. This work was supported by grants from the National Institutes of Health (HD27295) and from the Sandoz/Dana-Farber Cancer Institute Drug Discovery Program.

Received March 13, 1995; revised July 7, 1995.

References

- Angel, P., and Karin, M. (1991). The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. *Biochim. Biophys. Acta* 1072, 129-157.
- Binetruy, B., Smeal, T., and Karin, M. (1991). Ha-Ras augments c-Jun activity and stimulates phosphorylation of its activation domain. *Nature* 351, 122-127.
- Biunno, I., Pozzi, M. R., Pierotti, M. A., Pilotti, S., Cattoretti, G., and Della, P. G. (1988). Structure and expression of oncogenes in surgical specimens of human breast carcinomas. *Br. J. Cancer* 57, 464-468.
- Borchers, A. H., Powell, M. B., Fusenig, N. E., and Bowden, G. T. (1994). Paracrine factor and cell-cell contact-mediated induction of protease and *c-ets* gene expression in malignant keratinocyte/dermal fibroblast cocultures. *Exp. Cell Res.* 213, 143-147.
- Bremner, R., Kemp, C. J., and Balmain, A. (1994). Induction of different genetic changes by different classes of chemical carcinogens during progression of mouse skin tumors. *Mol. Carcinog.* 11, 90-97.
- Buchmann, A., Ruggeri, B., Klein, S. A., and Balmain, A. (1991). Progression of squamous carcinoma cells to spindle carcinomas of mouse skin is associated with an imbalance of H-ras alleles on chromosome 7. *Cancer Res.* 51, 4097-4101.
- Curran, T., Peters, G., Van, B. C., Teich, N. M., and Verma, I. M. (1982). FBJ murine osteosarcoma virus: identification and molecular cloning of biologically active proviral DNA. *J. Virol.* 44, 674-682.
- De Luca, L. M., Sly, L., Jones, C. S., and Chen, L.-C. (1993). Effects of dietary retinoic acid on skin papilloma and carcinoma formation in female SENCAR mice. *Carcinogenesis* 14, 539-542.
- Deng, T., and Karin, M. (1994). c-Fos transcriptional activity stimulated by H-Ras-activated protein kinase distinct from JNK and ERK. *Nature* 371, 171-175.
- DiGiovanni, J. (1992). Multistage carcinogenesis in mouse skin. *Pharmacol. Therapeut.* 54, 63-128.
- Fisher, C., Byers, M. R., Iadarola, M. J., and Powers, E. A. (1991). Patterns of epithelial expression of Fos protein suggest important role

- in the transition from viable to cornified cell during keratinization. *Development* 111, 253-258.
- French, J. E., Libbus, B. L., Hansen, L., Spalding, J., Tice, R. R., Mahler, J., and Tennant, R. W. (1994). Cytogenetic analysis of malignant skin tumors induced in chemically treated TG.AC transgenic mice. *Mol. Carcinog.* 11, 215-226.
- Jimenez-Conti, I., Aldaz, C. M., Bianchi, A. B., Roop, D. R., Slaga, T. J., and Conti, C. J. (1990). Early expression of type I K13 keratin in the progression of mouse skin papillomas. *Carcinogenesis* 11, 1995-1999.
- Hansen, L. A., and Tennant, R. (1994a). Focal transgene expression associated with papilloma development in v-Ha-ras-transgenic TG.AC mice. *Mol. Carcinog.* 9, 143-154.
- Hansen, L. A., and Tennant, R. W. (1994b). Follicular origin of epidermal papillomas in v-Ha-ras transgenic TG.AC mouse skin. *Proc. Natl. Acad. Sci. USA* 91, 7822-7826.
- Hennigan, R. F., Hawker, K. L., and Ozanne, B. W. (1994). Fos-transformation activates genes associated with invasion. *Oncogene* 9, 3591-3600.
- Hennings, H., Michael, D., Cheng, C., Steinert, P., Holbrook, K., and Yuspa, S. H. (1980). Calcium regulation of growth and differentiation of mouse epidermal cells in culture. *Cell* 19, 245-254.
- Hennings, H., Glick, A. B., Greenhalgh, D. A., Morgan, D. L., Strickland, J. E., Tennenbaum, T., and Yuspa, S. H. (1993). Critical aspects of initiation, promotion, and progression in multistage epidermal carcinogenesis. *Proc. Soc. Exp. Biol. Med.* 202, 1-8.
- Hilberg, F., Aguzzi, A., Howells, N., and Wagner, E. F. (1993). *c-jun* is essential for normal mouse development and hepatogenesis. *Nature* 365, 179-181.
- Hill, C. S., and Treisman, R. (1995). Transcriptional regulation by extracellular signals: mechanisms and specificity. *Cell* 80, 199-211.
- Hong, W. K., Lippman, S. M., Itri, L. M., Karp, D. D., Lee, J. S., Byers, R. M., Schantz, S. P., Kraemer, A. M., Lotan, R., Peters, L. J., Dimery, I. W., Brown, B. W., and Goepfert, H. (1990). Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. *N. Engl. J. Med.* 323, 795-801.
- Honoki, K., Tsutsumi, M., Tsujiuchi, T., Kondoh, S., Shiraiwa, K., Miyauchi, Y., Mii, Y., Tamai, S., Konishi, Y., and Bowden, G. T. (1992). Expression of the transin, *c-fos*, and *c-jun* genes in rat transplantable osteosarcomas and malignant fibrous histiocytomas. *Mol. Carcinog.* 6, 122-128.
- Hu, E., Mueller, E., Oliviero, S., Papaioannou, V. E., Johnson, R., and Spiegelman, B. M. (1994). Targeted disruption of the *c-fos* gene demonstrates *c-fos*-dependent and -independent pathways for gene expression stimulated by growth factors or oncogenes. *EMBO J.* 13, 3094-3103.
- Johnson, R. S., Spiegelman, B. M., and Papaioannou, V. (1992). Pleiotropic effects of a null mutation in the *c-fos* proto-oncogene. *Cell* 71, 577-586.
- Johnson, R. S., Van, L. B., Papaioannou, V. E., and Spiegelman, B. M. (1993). A null mutation at the *c-jun* locus causes embryonic lethality and retarded cell growth in culture. *Genes Dev.* 7, 1309-1317.
- Kerppola, T. K., Luk, D., and Curran, T. (1993). Fos is a preferential target of glucocorticoid receptor inhibition of AP-1 activity *in vitro*. *Mol. Cell. Biol.* 13, 3782-3791.
- Kerr, L. D., Holt, J. T., and Matrisian, L. M. (1988). Growth factors regulate transin gene expression through *c-fos* dependent and *c-fos* independent pathways. *Science* 242, 1424-1428.
- Klagsbrun, M., and Soker, S. (1993). VEGF/VPF: the angiogenesis factor found? *Curr. Biol.* 3, 699-702.
- Klein-Szanto, A. J. P., Larcher, F., Bonfil, R. D., and Conti, C. J. (1989). Multistage chemical carcinogenesis protocols produce spindle cell carcinomas of the mouse skin. *Carcinogenesis* 10, 2169-2172.
- Krieg, P., Finch, J., Fustenberg, G., Melber, K., Matrisian, L. M., and Bowden, G. T. (1988). Tumor promoters induce a transient expression of tumor-associated genes in both basal and differentiated cells of the mouse epidermis. *Carcinogenesis* 9, 95-100.
- Leder, A., Kuo, A., Cardiff, R. D., Sinn, F., and Leder, P. (1990). v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. *Proc. Natl. Acad. Sci. USA* 87, 9178-9182.
- Liotta, L. A., and Stetler-Stevenson, W. G. (1990). Metalloproteinases and cancer invasion. *Semin. Cancer Biol.* 1, 99-106.
- Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G. (1991). Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. *Cell* 64, 327-336.
- Maki, Y., Bos, T. J., Davis, C., Starbuck, M., and Vogt, P. K. (1987). Avian sarcoma virus 17 carries the *jun* oncogene. *Proc. Natl. Acad. Sci. USA* 84, 2848-2852.
- Matrisian, L., Bowden, G. T., Krieg, P., Fustenberg, G., Briand, J.-P., Leroy, P., and Breathnach, R. (1986). The mRNA coding for the secreted protease transin is expressed more abundantly in malignant than in benign tumors. *Proc. Natl. Acad. Sci. USA* 83, 9413-9417.
- McDonnell, S., and Matrisian, L. M. (1990). Stromelysin in tumor progression and metastasis. *Cancer Metastasis Rev.* 9, 305-319.
- Mehrel, T., Hohl, D., Rothnagel, J. A., Longley, M. A., Bundman, D., Cheng, C., Licht, U., Bisher, M. E., Steven, A. C., Steinert, P. M., Yuspa, S. H., and Roop, D. R. (1990). Identification of a major keratinocyte cell envelope protein, loricrin. *Cell* 61, 1103-1112.
- Nischt, R., Roop, D. R., Mehrel, T., Yuspa, S. H., Rentrop, M., Winter, H., and Schweizer, J. (1988). Aberrant expression during two-stage mouse skin carcinogenesis of a type I 47-kDa keratin, K13, normally associated with terminal differentiation of internal stratified epithelia. *Mol. Carcinog.* 1, 96-108.
- Pawelczak, N., and Boxberger, H.-J. (1994). Defined tumor cell-host interactions are necessary for malignant growth. *Crit. Rev. Oncog.* 5, 69-105.
- Pulverer, B. J., Kyriakis, J. M., Avruch, J., Nikolakaki, E., and Woodgett, J. R. (1991). Phosphorylation of *c-jun* mediated by MAP kinases. *Nature* 353, 670-674.
- Ransone, L. J., and Verma, I. M. (1990). Nuclear proto-oncogenes *fos* and *jun*. *Annu. Rev. Cell Biol.* 6, 539-557.
- Roop, D. R., Lowy, D. R., Tambourin, P. E., Strickland, J., Harper, J. R., Balaschak, M., Spangler, E. F., and Yuspa, S. H. (1986). An activated Harvey ras oncogene produces benign tumours on mouse epidermal tissue. *Nature* 323, 822-824.
- Ruther, U., Garber, C., Komitowski, D., Muller, R., and Wagner, E. F. (1987). Deregulated *c-fos* expression interferes with normal bone development in transgenic mice. *Nature* 325, 412-416.
- Ruther, U., Komitowski, D., Schubert, F. R., and Wagner, E. F. (1989). *c-fos* expression induces bone tumors in transgenic mice. *Oncogene* 4, 861-865.
- Schonthal, A., Herrlich, P., Rahmsdorf, H. J., and Ponta, H. (1988). Requirement for *fos* gene expression in the transcriptional activation of collagenase by other oncogenes and phorbol esters. *Cell* 54, 325-334.
- Schuh, A. C., Keating, S. J., Monteclaro, F. S., Vogt, P. K., and Breitman, M. L. (1990). Obligatory wounding requirement for tumorigenesis in v-*jun* transgenic mice. *Nature* 346, 756-760.
- Schule, R., Umesono, K., Mangelsdorf, D. J., Bolado, J., Pike, J. W., and Evans, R. M. (1990). Jun-Fos and receptors for vitamins A and D recognize a common response element in the human osteocalcin gene. *Cell* 61, 497-504.
- Smeyne, R. J., Schilling, K., Robertson, L., Luk, D., Oberdick, J., Curran, T., and Morgan, J. I. (1992). *fos-lacZ* transgenic mice: mapping sites of gene induction in the central nervous system. *Neuron* 8, 13-23.
- Smola, H., Thiekötter, G., and Fusenig, N. E. (1993). Mutual induction of growth factor gene expression by epidermal-dermal cell interaction. *J. Cell Biol.* 122, 417-429.
- Spalding, J. W., Momma, J., Elwell, M. R., and Tennant, R. W. (1993). Chemically induced skin carcinogenesis in a transgenic mouse line (TG.AC) carrying a v-Ha-ras gene. *Carcinogenesis* 14, 1335-1341.
- Strawhecker, J. M., and Pelling, J. C. (1992). Inhibition of mouse skin tumorigenesis by dexamethasone occurs through a Ha-ras-independent mechanism. *Carcinogenesis* 13, 2075-2080.

Strickland, J. E., Dlugosz, A. A., Hennings, H., and Yuspa, S. H. (1993). Inhibition of tumor formation from grafted murine papilloma cells by treatment of grafts with staurosporine, an inducer of squamous differentiation. *Carcinogenesis* 14, 205-209.

Urabe, A., Nakayama, J., Taniguchi, S., Terao, H., and Hori, Y. (1992). Expression of the *c-fos* oncogene in chemically-induced mouse tumours and in human skin tumours. *J. Pathol.* 168, 281-286.

Volm, M., Efferth, T., Mattern, J., and Wodrich, W. (1992). Overexpression of *c-fos*- and *c-erbB-1* encoded proteins in squamous cell carcinomas of the lung of smokers. *Int. J. Oncol.* 1, 69-71.

Walker, R. A., and Cowl, J. (1991). The expression of *c-fos* protein in human breast. *J. Pathol.* 163, 323-327.

Wang, Z. Q., Ovitt, C., Grigoriadis, A. E., Mohle, S. U., Ruther, U., and Wagner, E. F. (1992). Bone and haematopoietic defects in mice lacking *c-fos*. *Nature* 360, 741-745.

Wodrich, W., and Volm, M. (1993). Overexpression of onco-proteins in non-small cell lung carcinomas of smokers. *Carcinogenesis* 14, 1121-1124.

Yuspa, S. H. (1994). The pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis. *Cancer Res.* 54, 1178-1189.

Yuspa, S. H., Ben, T., Patterson, E., Michael, D., Elgjo, K., and Hennings, H. (1976). Stimulated DNA synthesis in mouse epidermal cell cultures treated with 12-O-tetradecanoyl-phorbol-13-acetate. *Cancer Res.* 36, 4062-4068.

Yuspa, S. H., Kilkenny, A. E., Steinert, P. M., and Roop, D. R. (1989). Expression of murine epidermal differentiation markers is tightly regulated by restricted extracellular calcium concentrations *in vitro*. *J. Cell Biol.* 109, 1207-1217.

c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis *in vivo* and *in vitro*

LUCIA MARCONCINI*, SERENA MARCHIO†, LUCIA MORBIDELLI‡, ELENA CARTOCCI*, ADRIANA ALBINI§, MARINA ZICHE‡, FEDERICO BUSSOLINO†, AND SALVATORE OLIVIERO*¶

*Dipartimento di Biologia Molecolare Università degli Studi di Siena, via Fiorentina 1–53100 Siena, Italy; †Dipartimento di Genetica, Biologia e Chimica Medica, Università degli Studi di Torino, and Institute for Cancer Research and Treatment, 10060 Candiolo, Italy; ‡Dipartimento di Farmacologia Università degli Studi di Firenze e Istituto di Scienze Farmacologiche Università degli Studi di Siena, 53100 Siena, Italy; and §Istituto Nazionale per la Ricerca sul Cancro e Centro per le Biotecnologie Avanzate, 16100 Genova, Italy

Communicated by Lewis T. Williams, Chiron Technologies, Emeryville, CA, June 18, 1999 (received for review March 4, 1999)

ABSTRACT c-fos-induced growth factor/vascular endothelial growth factor D (Figf/Vegf-D) is a secreted factor of the VEGF family that binds to the vessel and lymphatic receptors VEGFR-2 and VEGFR-3. Here we report that Figf/Vegf-D is a potent angiogenic factor in rabbit cornea *in vivo* in a dose-dependent manner. *In vitro* Figf/Vegf-D induces tyrosine phosphorylation of VEGFR-2 and VEGFR-3 in primary human umbilical cord vein endothelial cells (HUVECs) and in an immortal cell line derived from Kaposi's sarcoma lesion (KS-IMM). The treatment of HUVECs with Figf/Vegf-D induces dose-dependent cell growth. Figf/VEGF-D also induces HUVEC elongation and branching to form an extensive network of capillary-like cords in three-dimensional matrix. In KS-IMM cells Figf/Vegf-D treatment results in dose-dependent mitogenic and motogenic activities. Taken together with the previous observations that Figf/Vegf-D expression is under the control of the nuclear oncogene c-fos, our data uncover a link between a nuclear oncogene and angiogenesis, suggesting that Figf/Vegf-D may play a critical role in tumor cell growth and invasion.

During development and in the vascularization of tumors inductive signaling leads to the formation of capillaries throughout the new-forming tissues (1, 2). Inhibitors who regulate proliferation, migration, differentiation of endothelial cells, degradation of the extracellular matrix, and tube formation finely tune this complex process, known as angiogenesis (3–5). The prototype of angiogenic factors is represented by vascular endothelial growth factor (VEGF) A, also known as vascular permeability factor. VEGF-A induces endothelial cell differentiation and is essential for embryonic vessel development (4, 6, 7). It belongs to a multigene family of angiogenic factors in which several new members were discovered recently. It generally is thought that each member of this family plays a specific role in the angiogenic process (2). In addition to VEGF-A, this family includes the placental growth factor (PlGF), VEGF-B/VRF, VEGF-C/VRP, c-fos-induced growth factor (Figf)/VEGF-D, and VEGF-E (8–18). All of these factors show a conserved cysteine-rich domain characteristic of the family. Differences in the patterns of expression suggest a specific role for at least some of the factors in the vascularization of different tissues. Plgf is expressed mostly in the placenta, whereas VEGF-B is prevalent in skeletal and cardiac muscle tissues (12, 19). These two factors can form heterodimers with VEGF-A adding an additional level of specificity (12, 20). Interestingly, VEGF-C is involved in both blood and lymphatic vessel growth (21, 22).

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

PNAS is available online at www.pnas.org.

Figf/Vegf-D initially was identified by using a differential screening strategy aimed at the identification of new c-fos-responsive genes in mouse fibroblasts and therefore named c-fos-induced growth factor (15). Its human orthologue shares 84% identity and was named VEGF-D because it encodes for a secreted protein whose primary sequence is most similar to VEGF-C (16, 23–25). Both VEGF-C and VEGF-D are recognized by VEGF receptors (VEGFR)-2 and -3, which are present on endothelial cells (14, 23). In mouse embryos Figf/Vegf-D is expressed in several organs, including limb buds, teeth, heart, and pituitary as well as lung and kidney mesenchyme, liver, derma, and periosteum of the vertebral column that partially overlaps Vegf-C expression (26, 27). In cultured fibroblasts Figf/Vegf-D regulation differs from VEGF-C. Whereas the expression of Figf/Vegf-D depends on c-fos (15), VEGF-C is induced by serum, tumor promoter phorbol myristate 13-acetate, IL-1 β , and tumor necrosis factor α , and its expression is independent from c-fos (15, 28, 29).

We produced a recombinant form of mature mouse Figf/Vegf-D and analyzed its biological activity both *in vivo* and *in vitro*. Figf/Vegf-D, expressed in Chinese hamster ovary (CHO) cells or purified from yeast, is a potent angiogenic factor in rabbit cornea assays. *In vitro* it activates tyrosine phosphorylation of VEGFR-2 and VEGFR-3 present on human umbilical cord vein endothelial cells (HUVECs) and on the Kaposi's sarcoma immortalized cell line (KS-IMM). In KS-IMM cells Figf/Vegf-D induces proliferation and chemotaxis. In HUVECs Figf/Vegf-D induces growth and morphological changes within a three-dimensional matrix.

MATERIALS AND METHODS

Expression of Figf/Vegf-D. To express the mature factor in CHO cells, the Figf/Vegf-D cDNA with a segment coding for the FLAG octapeptide (IBI/Kodak) at C terminal was amplified by PCR and inserted into the mammalian expression vector pcDNA3 (Invitrogen) under the control of the cytomegalovirus promoter (construct LM357). CHO cells were transfected with LM357 by using calcium phosphate precipitation. Stable clones were selected in DMEM containing 10% FCS and 800 μ g/ml G418. To assay the presence of Figf/Vegf-D in CHO supernatants, isolated clones were grown in DMEM containing 2% FCS and 800 μ g/ml G418 and analyzed by ELISA using anti-Figf/Vegf-D rabbit polyclonal antiserum (15). Supernatant from positive clones was precipitated with deoxycholate acid and analyzed by Western blot. Different CHO clones expressed different Figf/Vegf-D levels. Specifi-

Abbreviations: Figf, c-fos-induced growth factor; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor; HUVEC, human umbilical cord vein endothelial cell; KS-IMM, Kaposi's sarcoma-immortal; CHO, Chinese hamster ovary.

¶To whom reprint requests should be addressed. E-mail: oliviero@unisi.it.

cally, clone 65 expressed less than 0.1 ng/ml of Figf/Vegf-D in the cell supernatant *in vitro* whereas clone 79 expressed approximately 0.5 ng/ml of Figf/VEGF-D in the same conditions.

To express Figf/Vegf-D in yeast a cDNA fragment encoding the portion of the mouse Figf/Vegf-D polypeptide from residues 91 to 208 with six histidine residues at N terminus was amplified by PCR and inserted into the expression vector Yepsec1 immediately downstream from DNA sequence encoding the *Kluyveromyces lactis* toxin leader peptide (LM375) (30). The protein was expressed in *Saccharomyces cerevisiae* yeast strain by adding galactose to the yeast culture medium because Yepsec1 construct contains a galactose upstream activation sequence and the 5' nontranslated leader of the yeast CYC1 gene, up to position -4 from the ATG translation initiation codon (30). Figf/Vegf-D glycosylation mutant was obtained by PCR with the substitution N160P (LM376). Figf/Vegf-D and Figf/Vegf-D N160P proteins were purified from the yeast supernatant by using a nickel column (HiTrap Chelating columns Pharmacia Biotech) under native conditions.

In Vivo Angiogenic Assay. The angiogenic activity of Figf/Vegf-D was assayed *in vivo* by using the rabbit cornea assay previously described (31). Corneal assays were performed in male New Zealand albino rabbits (Charles River, Calco, Lecco, Italy) in accordance with the guideline of the European Economic Community for Animal Care and Welfare (EEC Law No. 86/609). Briefly, after being anaesthetized with sodium pentotal (30 mg/Kg), a micro pocket (1.5 × 3 mm) was surgically produced by using a pliable iris spatula 1.5 mm wide in the lower half of the cornea. The cell suspension (from 2.5 to 4 × 10⁵ cells/5 ml) or slow-release pellets of Elvax-40 (DuPont) containing the purified growth factor were implanted into the micro pocket. Subsequently daily observation of the implants was made with a slit lamp stereomicroscope without anesthesia. An angiogenic response was scored positive when budding of vessels from the limbal plexus occurred after 4 days and capillaries progressed to reach the implanted pellet according to the scheme previously reported (32). The potency of angiogenic activity was evaluated on the basis of the number and growth rate of newly formed capillaries, and an angiogenesis score was calculated as described (32). Corneas were removed at the end of the experiment as well as at defined intervals after surgery and/or treatment and fixed in formalin for histological examination. A minimum of four independent experiments was performed for each condition.

Cell Cultures. Human endothelial cells were isolated from umbilical cord vein by collagenase treatment as described (33) and used at passage 1–4. KS-IMM cells were derived from a non-AIDS patient and are immortalized without signs of senescence after more than 120 *in vitro* passages. This cell line shares common markers and similar biological behavior with typical KS "spindle cells" (34). Cells were grown on gelatin-coated plastic, in medium M 199 supplemented with 20% heat-inactivated FCS, penicillin (100 units/ml), streptomycin (50 µg/ml), heparin (50 µg/ml), and bovine brain extract (100 µg/ml) (Life Technologies, Milan, Italy).

In Vitro Angiogenesis. Because Matrigel can induce spontaneously *in vitro* angiogenesis, we tested more preparations and used batches devoid of this activity. Fifty microliters of Matrigel (Collaborative Research, lot 901448) (35) was added per well of 96-well tissue culture plates and allowed to gel at 37°C for 10 min. HUVECs were starved for 24 h in M199 with 1% FCS before being harvested in PBS-EDTA. Cells (10⁴) were gently added to each of triplicate wells and allowed to adhere to the gel coating for 30 min at 37°C. Then, medium was replaced with indicated concentrations of Figf/Vegf-D. The plates were monitored after 24 h and photographed with a Canon microscope. Each experiment was repeated at least three times with identical results.

Immunoprecipitation and Western Blotting. Subconfluent cultures were starved as above and then cells were stimulated with the indicated concentrations of Figf/Vegf-D for 10 min at room temperature. Positive control was done by incubating cells with sodium orthovanadate (0.1 mM H₂O₂, 1 mM Na₃VO₄) for 20 min at 37°C. After three washes with cold PBS containing 1 mM sodium orthovanadate, cells were lysed for 20 min on ice in 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM Na₃VO₄, 1 mM PMSF, 0.1 mM ZnCl₂, 1% Triton. Lysates (1 mg of total proteins) were incubated at 4°C for 2 h with 100 µl of a 50% solution of protein A-Sepharose (Amersham-Pharmacia Biotech) in 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, and anti-VEGFR-2 (Santa Cruz Biotechnology, sc-504) or anti-VEGFR-3 (Santa Cruz Biotechnology, sc-321). Immunoprecipitates were washed four times with lysis buffer and analyzed by 8% SDS/PAGE. Proteins were transferred onto a nylon membrane [poly(vinylidene difluoride), Millipore] and analyzed by immunoblotting with antiphosphotyrosine mAb (Upstate Biotechnology, Lake Placid, NY). Staining was performed by a chemiluminescence assay (ECL, Amersham-Pharmacia Biotech).

Cell Growth Assay. HUVECs (2.5 × 10³) or KS-IMM cells were plated in 96-well plates (Costar) coated with gelatin (Difco; 0.05%, for 1 h at 22°C) in M199 medium containing 20% FCS (Irvine Scientific). After 24 h the medium was removed and replaced with M199 containing 1% FCS with or without Figf/Vegf-D; fresh factor was added every 2 days. Endothelial cell numbers were estimated after staining with crystal violet by a colorimetric assay described by Keung *et al.* (36).

Chemotaxis Assay. Chemotaxis assays on HUVECs and KS-IMM were performed as described (33, 37) with the Boyden chamber technique using a 48-well micro chemotaxis chamber. Polyvinylpyrrolidone-free polycarbonate filters (Nucleopore, Corning-Costar) with a pore size of 5 µm were coated with 1% gelatin for 10 min at room temperature and equilibrated in M199 supplemented with 1% FCS. Indicated concentrations of purified Figf/Vegf-D were placed in the lower compartment of a Boyden chamber. Subconfluent cultures were starved as above, harvested in PBS (pH 7.4) with 10 mM EDTA, washed once in PBS, and resuspended in M199 containing 1% FCS, at a final concentration of 2.5 × 10⁶ cells/ml. After placing the filter between the lower and upper chambers, 50 µl of the cell suspension was seeded in the upper compartment. Cells were allowed to migrate for 7 h at 37°C in a humidified atmosphere with 5% CO₂. The filter then was removed, and cells on the upper side were scraped with a rubber policeman. Migrated cells were fixed in methanol, stained with Giemsa solution (Diff-Quick, Baxter Diagnostics, Rome) and counted from five random high-power fields (magnification ×100) in each well. Each experimental point was studied in triplicate.

RESULTS

Induction of Angiogenesis *in Vivo*. Mature VEGF-C and Figf/VEGF-D factors are generated by proteolytic cleavages of both of the N- and C-terminal domains during secretion (15, 23, 38). To obtain recombinant mature Figf/Vegf-D we generated CHO clones by stable transfection of constructs containing the mouse Figf/Vegf-D cDNA truncated at the C-terminal proteolytic site (38). To assess *in vivo* the angiogenic activity of increasing concentrations of the recombinant protein administered to avascular tissue two clones expressing different levels of secreted Figf/Vegf-D were selected for implantation into rabbit corneas. These clones secrete in the culture medium Figf/Vegf-D in two main forms of molecular mass of 30 and 21 kDa, respectively (Fig. 1A). Both clone 65 and clone 79 induced corneal vascularization whereas the CHO mock transfectant clone did not show any angiogenic




FIG. 1. Implanted Figf/Vegf-D-expressing cells induce neovascularization in rabbit corneas. (*A*) Figf/Vegf-D expressed in CHO cells. Equal volumes of culture supernatants from clones 65 and 79 were precipitated and analyzed by Western blot using an anti-Figf/Vegf-D rabbit polyclonal antiserum. (*B*) CHO cells (4×10^4) expressing Figf/Vegf-D were surgically implanted into the corneas. New blood vessel growth was recorded every other day with a slit lamp stereomicroscope. Angiogenic scores were calculated on the basis of the number of vessels and their growth rate and plotted versus time (for experimental details see *Materials and Methods*). Angiogenic score data are the mean values obtained from the response scored in all animals in this study. C, CHO mock transfectant clone; #65, clone expressing low levels of Figf/Vegf-D (0.1 ng/ml protein in supernatant); #79 clone expressing higher levels of Figf/Vegf-D (approximately 0.5 ng/ml protein in supernatant). (*C*) Pictures of rabbit corneas from a representative experiment. (*a*) Corneal implant of CHO mock transfectant. Clone 79 promotes and sustains vascular growth over time at day 6 (*b*), 9 (*c*), and 14 (*d*). Corneas were photographed with a stereomicroscope. Magnification: $\times 18$.

effect (Fig. 1*B*). Although a direct dose response could not be made in this assay, the efficiency of the angiogenic response correlated with the amount of growth factor released *in vitro* as clone 79 secreted about 5-fold more Figf/Vegf-D than clone 65 in the same conditions (Fig. 1*A*). Consistently, neovascular growth induced by clone 79 was more efficient and persisted in 100% of the implants whereas clone 65 did so in only 30% of corneas (Fig. 1*B*). This angiogenic activity also was suggested by the direct correlation between neovascular growth observed and the number of cells implanted into corneal micro pocket (data not shown). The angiogenic response obtained with clone 79 (Fig. 1*C*) was comparable to the one elicited with cells expressing VEGF-A₁₂₁ (39) both in intensity and appearance.

To obtain larger amounts of pure Figf/Vegf-D it also was expressed in yeast *S. cerevisiae*. To obtain a secreted Figf/Vegf-D form in yeast supernatants the cDNA fragment encoding the portion of the mouse Figf/Vegf-D polypeptide from residues 91 to 208 plus a segment coding for six histidine residues at the N terminus was cloned in a yeast vector containing a secretion signal. This recombinant protein expressed in yeast was secreted into the culture medium (Fig. 2*A*). By contrast with the other members of the VEGF family, VEGF-C and Figf/Vegf-D contain two putative glycosylation sites in the mature protein. Secreted Figf/Vegf-D is glycosylated at asparagine-160 residue in both mammalian and yeast cells (data not shown). To test the activity of both the glycosylated and unglycosylated forms we also generated a Figf/Vegf-D mutant in which the glycosylation site was mutated by the introduction of a proline residue at position 160, which is present in all other known VEGF family members. Consistent with N-linked glycosylation, the wild-type protein shows about 2-kDa molecular mass increase with respect to the

mutant Figf/Vegf-D N160P (Fig. 2*A*) and it is sensitive to endoglycosidase H (not shown).

Figf/Vegf-D purified to homogeneity was analyzed in the corneal micro pocket assay *in vivo*. Similar to the results obtained with implanted CHO cells, purified Figf/Vegf-D induced a strong angiogenic response. After the implant of a single dose of protein in the slow-release pellets all Figf/Vegf-D doses of 100–400 ng/pellet induced capillary growth after just 3 days. However, a clear effect of increasing Figf/Vegf-D concentration was evident at later time points (Fig. 2*B*). The Figf/Vegf-D N160P mutant showed less potent angiogenic activity with respect to the wild-type protein (Fig. 2*C*), suggesting that Figf/Vegf-D glycosylation is involved in receptor recognition. In this assay, recombinant Figf/Vegf-D showed intermediate activity when compared with VEGF-A₁₂₁ and VEGF-A₁₆₅ (Fig. 2*D*) when used at doses of 300–400 ng. Corneal angiogenesis induced by either Figf/Vegf-D or VEGF-A was noninflammatory (not shown).

Figf/Vegf-D Induces *In Vitro* Angiogenesis. Studying endothelial cell behavior in a three-dimensional culture system, consisting of extra cellular matrix proteins, allows for *in vitro* conditions that more closely mimic the *in vivo* environment permissive for cell differentiation into capillary-like structures. This assay system is called *in vitro* angiogenesis (40). To examine whether Figf/Vegf-D induces *in vitro* morphological changes resembling of capillary like-structure formation, endothelial cells were plated on a three-dimensional matrix of Matrigel (41) and then stimulated with increasing concentrations of Figf/Vegf-D. Endothelial cells grown under these conditions in the presence of 1% BSA exhibited a small round shape and did not spread. Treatment with Figf/Vegf-D for 24 h resulted in dramatic dose-dependent morphological changes. The cells became elongated, forming thin cords of intercon-




FIG. 2. Figf/Vegf-D sustains dose-dependent angiogenesis *in vivo*. (A) Supernatant of *S. cerevisiae* yeast strains expressing Figf/Vegf-D and Figf/Vegf-D mutant as indicated. (B) The angiogenic activity of various concentrations of Figf/Vegf-D were tested as slow-release preparations in the rabbit cornea assay. (C) Angiogenic activity of 200 and 400 ng/pellet of Figf/Vegf-D N160P. (D) Angiogenic activity of 200 ng/pellet of VEGF-A₁₂₁ and VEGF-A₁₆₅ is shown for comparison. Angiogenic score data are the mean values obtained from the responses scored in all animals in this study. Variations were below 10% of the mean values. Angiogenic scores are calculated as described in Fig. 1 and in *Materials and Methods*.

necting cells (Fig. 3). The effect was investigated in a range of concentrations between 5 and 200 ng/ml and was maximal at 100 ng/ml. Similar effects also were observed with 20 ng/ml VEGF-A. These data demonstrate that Figf/Vegf-D, like VEGF-A, is able to mediate dramatic cell reorganization, which would be necessary *in vivo* for the sprouting of endothelial cells and tube formation. No morphological alterations could be observed in KS-IMM cells, either by treating the cells with VEGF-A or with Figf/Vegf-D (not shown).

Figf/Vegf-D Induction of VEGFR-2 and VEGFR-3 Tyrosine Phosphorylation. It has been reported recently that VEGF-D and VEGF-C are the ligands of the endothelial tyrosine kinase receptors VEGFR-2 and VEGFR-3 (14, 23). To examine the

cellular response of endothelial cells to Figf/Vegf-D *in vitro*, we first tested whether Figf/Vegf-D could stimulate signal transduction from VEGFR-2 and VEGFR-3 in HUVECs and KS-IMM cells because these cells express both receptors. Tyrosine phosphorylation of these receptors was assayed in serum-starved cells treated with Figf/Vegf-D. VEGFR-2 and VEGFR-3 were immunoprecipitated with specific antibodies and analyzed by Western blotting with antiphosphotyrosine-specific antibodies. Figf/Vegf-D stimulated tyrosine phosphorylation of the 210-kDa VEGFR-2 and both the 125- and 195-kDa processed and unprocessed forms of VEGFR-3 in both HUVECs and KS-IMM cells (Fig. 4). Thus, Figf/Vegf-D, like VEGF-C, binds and activates these receptors on endothelial cells.




FIG. 3. Figf/Vegf-D-induced endothelial cell morphological changes. VEGF-A or Figf/Vegf-D were added to HUVECs cultured in three-dimensional Matrigel in low serum conditions. Photographs were taken 24 h after Figf/Vegf-D treatment. Protein concentrations (ng/ml) used are indicated.




FIG. 4. Figf/Vegf-D-induced tyrosine phosphorylation of VEGFR-2 and VEGFR-3. HUVECs and KS-IMM cells were incubated with Figf/Vegf-D. After stimulation receptors were immunoprecipitated with antireceptor antibodies and analyzed by Western blotting with an antiphosphotyrosine mAb. (A and B) Phosphorylation of VEGFR-2 and VEGFR-3 in HUVECs. (C and D) Phosphorylation of VEGFR-2 and VEGFR-3 in KS-IMM cells. Positive control (+) and Figf/Vegf-D stimulation (D) is indicated. Arrows denote the position of the phosphorylated 210-kDa VEGFR-2 protein and the positions of the phosphorylated, proteolytically processed 125-kDa and unprocessed 195-kDa forms of VEGFR-3.

Fgf/Vegf-D Induction of Growth and Chemotaxis in HUVECs and KS-IMM Cells. To investigate further the proliferative effect of Fgf/VEGF-D on endothelial cells, we incubated both the cultured HUVECs and KS-IMM cells in the presence of increasing concentrations of Fgf/Vegf-D. Proliferation of both cell types was stimulated in a dose-dependent manner (Fig. 5 *A* and *B*). The effect was investigated in a range of concentrations between 5 and 100 ng/ml and was maximal at 50 ng/ml for both cell types. Interestingly, when suboptimal concentrations of VEGF-A₁₆₅ and Fgf/Vegf-D were coadded to HUVECs the resulting proliferation was higher than the treatment of each alone (not shown).

The chemotactic effect of Fgf/Vegf-D on HUVECs and KS-IMM cells was analyzed in a modified Boyden chamber assay. The migration of the cells through collagen-coated micropore filters toward chemoattractants was scored in the absence of serum. Fgf/Vegf-D stimulated the migration of KS-IMM cells in a dose-dependent manner. In HUVECs, under identical conditions Fgf/Vegf-D induced little or no migration (Fig. 5 *C* and *D*).

DISCUSSION

The results reported in this work show that Fgf/Vegf-D is a potent angiogenic factor. In rabbit corneas Fgf/Vegf-D, ex-

pressed either in CHO or yeast cells, can efficiently induce angiogenesis. The dose dependency and the early response suggest a direct effect of Fgf/Vegf-D on endothelial cell recruitment *in vivo*. This observation has been confirmed by *in vitro* experiments that show direct Fgf/Vegf-D activities on endothelial cells. In addition to Fgf/Vegf-D, other factors, including VEGF-A, basic fibroblast growth factor, placental growth factor, VEGF-C, and VEGF-E induce angiogenesis, suggesting a redundancy or a coordination among factors performing the same function (2, 10, 42, 43). The generation of VEGF-A knockout mice demonstrated that this factor is essential for angiogenesis during development (6, 7). Thus, simple redundancy of all members of the family is unlikely. We favor the hypothesis that the complex process of angiogenesis normally requires the cooperation of multiple factors and the experimental overexpression of some key members is able to trigger the process both directly and indirectly, inducing the expression of other factors. Each of these factors shows a peculiar pattern of expression, suggesting that a complex balance of factors in different developing organs may be relevant. Moreover, the biological function of VEGFs may not be limited to angiogenesis. For instance, fibroblast growth factors not only induce angiogenesis, but are also regulators of embryonic development, influencing the formation of several structures including body axis, limbs, heart, and lung differentiation (44–47). Similarly, the expression of Fgf/Vegf-D in tissues like the pituitary, the developing teeth, lung mesenchyme, and limb buds (26) suggests that Fgf/Vegf-D, in addition to playing a role in angiogenesis, could be involved in specific inductive signaling in these developing organs.

Fgf/Vegf-D and VEGF-C share striking similarities in their primary sequence and posttranslational modifications, and most importantly, both factors are recognized by VEGFR-2 and VEGFR-3 present on vascular and lymphatic vessels (14, 23). By using porcine aortic endothelial cells selectively overexpressing VEGFR-2 or VEGFR-3, it was shown recently that VEGF-C could promote migration and proliferation independently of signaling through either receptor (21). In this study for the analysis of Fgf/Vegf-D activity *in vitro* we used HUVECs and KS-IMM cells, which express both receptors. By immunoprecipitation experiments we showed that Fgf/Vegf-D activates both VEGFR-2 and VEGFR-3 tyrosine phosphorylation on both HUVECs and KS-IMM cells. The activation of these receptors by Fgf/Vegf-D stimulates a biological response that involves morphological, mitogenic, and motogenic responses. Thus, Fgf/Vegf-D shows a direct activity on endothelial cells *in vitro*, confirming the *in vivo* data. Although both HUVECs and KS-IMM cells show a similar mitogenic response to Fgf/Vegf-D they differ in motogenic responses because KS-IMM cells are more responsive than HUVECs to motogenic activation by Fgf/Vegf-D. This discrepancy could be simply because of differences in the receptor levels or in intracellular signaling molecules, but it also could be the result of the presence of possible coreceptors that may modify the receptor affinity and modulate the response to Fgf/Vegf-D. In line with this possibility, it recently has been shown in human endothelial cells that neuropilin-1 (48) and $\alpha\beta 3$ modulate the activity of VEGFR-2. Neuropilin-1 is a coreceptor for the VEGF-A₁₆₅ isoform and the $\alpha\beta 3$ integrin associates with VEGFR-1 upon VEGF-A stimulation and regulates the level of tyrosine phosphorylation of the receptor (49).

Fgf/Vegf-D differs from all other members of the VEGF family because it is the only angiogenic factor regulated by the nuclear oncogene *c-fos* (15). This unique regulation of Fgf/Vegf-D may be relevant both during development and in tumor progression because *c-fos* is involved not only in transformation but also in the regulation of cell growth and differentiation of various tissues (50, 51). Tumors that develop in *c-fos*-deficient mice appear devoid of vascularization although, in




FIG. 5. Fgf/Vegf-D-induced cell proliferation and chemotactic activity. (*A* and *B*) Proliferative effects of Fgf/Vegf-D were assayed on HUVECs and KS-IMM cells as indicated. Experiments were performed in medium containing 1% FCS. After 72 h cells were enumerated by using a Coulter counter and values represent the mean (\pm SEM) of triplicate samples. (*C* and *D*) Cells were seeded in the upper wells of a 48-well micro chemotaxis Boyden chamber and incubated for 7 h at 37°C in medium containing 1% FCS. The lower wells contained the indicated concentrations of Fgf/VEGF-D. Cells migrating through a polycarbonate membrane with a pore size of 5 μ m were quantified by staining the cells with Giemsa solution and counting was performed on a light microscope of five high-power fields ($\times 100$). The results are expressed as the mean \pm 1 SD of three independent experiments performed in triplicate.

these papillomas, VEGF-A expression is reduced but not absent (52). The role of Figf/Vegf-D in tumor progression is at the moment unclear, although the evidence that Figf/Vegf-D shows angiogenic activity on endothelial cells, as well as mitogenic and motogenic activity on tumor-derived KS-IMM cells, strongly suggest that Figf/Vegf-D can be a *c-fos* effector for tumor malignancy.

We thank Nicholas Valiante for the critical reading of the manuscript, Rino Rappuoli for hospitality in IRIS laboratories, Cesira Galeotti for yeast strains and helpful discussions, and Astrid Parenti and Beatrice Grandi for technical assistance. This work was supported by funds from Italian Association for Cancer Research, Chiron Vaccines and CEE N0 BMH4-CT98-3380 (S.O.); the Italian Association for Cancer Research, Istituto Superiore di Sanità (AIDS Project; Program on Tumor Therapy), Centro Nazionale delle Ricerche (Progetto Finalizzato Biotecnologie), and Ministero dell'Università e della Ricerca Scientifica e Tecnologica (60% and Programmi di Rilevante Interesse Nazionale) (F.B.), and the Italian Association for Cancer Research, Italian Ministry for University and for Scientific and Technological Research (Prot. 9706217225_06) and CEE PL 950669 (M.Z.). S.M. is supported by a grant from Centro Nazionale delle Ricerche (Progetto Biotecnologie).

- Ferrara, N. & Davis-Smyth, T. (1997) *Endocr. Rev.* **18**, 4–25.
- Nicosia, R. F. (1998) *Am. J. Pathol.* **153**, 11–16.
- Bussolino, F., Mantovani, A. & Persico, G. (1997) *Trends Biochem. Sci.* **22**, 251–256.
- Risau, W. (1997) *Nature (London)* **386**, 671–674.
- Folkman, J. (1997) *EXS* **79**, 1–8.
- Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kiechens, L., Gertsensein, M., Fairrig, M., Vandenhoec, A., Harpal, H., Ebherardt, C., et al. (1996) *Nature (London)* **380**, 435–439.
- Ferrara, N., Carver-More, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J. & Moore, M. W. (1996) *Nature (London)* **380**, 439–442.
- Betsholtz, C., Johnsson, A., Heldin, C.-H., Westermark, B., Lind, P., Urdea, M. S., Eddy, R., Shows, T. B., Philpott, K., Mellor, A. L., et al. (1986) *Nature (London)* **320**, 695–699.
- Keck, P. J., Hauser, S. D., Krivi, G., Sanzo, K., Warren, T., Feder, J. & Connolly, D. T. (1989) *Science* **246**, 1309–1312.
- Leung, D. W., Cachianes, G., Kuang, W., Goeddel, D. V. & Ferrara, N. (1989) *Science* **246**, 1306–1309.
- Maglione, D., Guerriero, V., Viglietto, G., Delli-Bovi, P. & Persico, M. G. (1991) *Proc. Natl. Acad. Sci. USA* **88**, 9267–9271.
- Olofsson, B., Pajusola, K., Kaipainen, A., von Euler, G., Joukov, V., Saksela, O., Orpana, A., Pettersson, R. F., Alitalo, K. & Erikson, U. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 2576–2581.
- Grimmond, S., Lagerkrantz, J., Drinkwater, C., Silins, G., Towson, S., Pollock, P., Götley, D., Carson, E., Rakar, S., Norden-skjold, M., et al. (1996) *Genome Res.* **6**, 124–131.
- Joukov, V., Pajusola, K., Kaipainen, A., Chilov, D., Lathinen, I., Kuk, E., Saksela, O., Kalkkinen, N. & Alitalo, K. (1996) *EMBO J.* **15**, 290–298.
- Orlandini, M., Marconcini, L., Ferruzzi, R. & Oliviero, S. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 11675–11680.
- Rocchigiani, M., Lestingi, M., Luddi, A., Orlandini, M., Franco, B., Rossi, E., Ballabio, A., Zuffardi, O. & Oliviero, S. (1998) *Genomics* **47**, 207–216.
- Ogawa, S., Oku, A., Sawano, A., Yamaguchi, S., Yazaki, Y. & Shibuya, M. (1998) *J. Biol. Chem.* **273**, 31273–31282.
- Meyer, M., Clauss, M., Lepple-Wienhues, A., Waltenberger, J., Augustin, H. G., Ziche, M., Lanz, C., Bettner, M., Rziha, H. J. & Dehio, C. (1999) *EMBO J.* **18**, 363–374.
- Maglione, D., Guerriero, V., Viglietto, G., Ferraro, M. G., Aprelikova, O., Alitalo, K., Del Vecchio, S., Lei, K.-J., Chou, J. Y. & Persico, G. G. (1993) *Oncogene* **8**, 925–931.
- Cao, Y., Chen, H., Zhou, L., Chiang, M. K., Anand-Apte, B., Weatherbee, J. A., Wang, Y., Fang, F., Flanagan, J. G. & Tsang, M. L. (1996) *J. Biol. Chem.* **271**, 3154–3162.
- Cao, Y., Linden, P., Farnebo, J., Cao, R., Eriksson, A., Kumar, V., Qi, J.-H., Claesson-Welsh, L. & Alitalo, K. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 14389–14394.
- Jeltsch, M., Kaipainen, A., Joukov, V., Meng, X., Lakso, M., Rauvala, H., Swartz, M., Fukumura, D., Jain, R. K. & Alitalo, K. (1997) *Science* **276**, 1423–1425.
- Achen, M. G., Jeltsch, M., Kuk, E., Makinen, T., Vitali, A., Wilks, A. F., Alitalo, K. & Stacker, S. A. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 548–553.
- Yamada, Y., Nezu, J., Shimane, M. & Hirata, Y. (1997) *Genomics* **42**, 483–488.
- Jenkins, N. A., Woollatt, E., Crawford, J., Gilbert, D. J., Baldwin, M. E., Sutherland, G. R., Copeland, N. G. & Achen, M. G. (1997) *Chromosome Res.* **5**, 502–505.
- Avantaggiato, V., Acampora, D., Orlandini, M., Oliviero, S. & Simeone, A. (1998) *Mech. Dev.* **73**, 221–224.
- Kuk, E., Lymboussaki, A., Taira, S., Kaipainen, A., Jeltsch, M., Joukov, V. & Alitalo, K. (1996) *Development (Cambridge, U.K.)* **122**, 3829–3837.
- Enholm, B., Paavonen, K., Ristimäki, A., Kumar, V., Gunji, Y., Klefstrom, J., Kivinen, L., Laiho, M., Olofsson, B., Jukov, V., et al. (1997) *Oncogene* **14**, 2475–2483.
- Ristimäki, A., Narko, K., Enholm, B., Joukov, V. & Alitalo, K. (1998) *J. Biol. Chem.* **273**, 8413–8418.
- Baldari, C., Murray, J. A., Ghiara, P., Cesareni, G. & Galeotti, C. (1987) *EMBO J.* **6**, 229–234.
- Ziche, M., Alessandri, G. & Gullino, P. M. (1989) *Lab. Invest.* **61**, 629–634.
- Ziche, M., Morbidelli, L., Choudhuri, R., Zhang, H. T., Donnini, S., Granger, H. J. & Bicknell, R. (1997) *J. Clin. Invest.* **99**, 2625–2634.
- Bussolino, F., Wang, J. M., Defilippi, P., Turrini, F., Sanavio, F., Edgell, C. J. S., Aglietta, M., Arese, P. & Mantovani, A. (1989) *Nature (London)* **337**, 471–473.
- Albini, A., Paglieri, I., Orenco, G., Carlone, S., Aluigi, M. G., DeMarchi, R., Matteucci, C., Mantovani, A., Carozzi, F., Donini, S. & Benelli, R. (1997) *AIDS* **11**, 713–721.
- Kleinman, H. K., McGarvey, M. L., Hassel, J. R., Star, V. L., Cannon, F. B., Laurie, G. W. & Martin, G. R. (1986) *Biochemistry* **25**, 312–318.
- Keung, K., Silfer, E. & Eppenberger, V. (1989) *Anal. Biochem.* **182**, 16–19.
- Dejana, E., Languino, L. R., Polentarutti, N., Balconi, C., Ryckewaert, J. J., Larrieu, M. J., Mantovani, A. & Marguerie, G. (1985) *J. Clin. Invest.* **75**, 11–18.
- Joukov, V., Sorsa, T., Kumar, V., Jeltsch, M., Claesson-Welsh, L., Cao, Y., Saksela, O., Kalkkinen, N. & Alitalo, K. (1997) *EMBO J.* **16**, 3898–3911.
- Morbidelli, L., Birkenhaeger, R., Roeckl, W., Granger, H. J., Kaerst, U., Weich, H. & Ziche, M. (1997) *Angiogenesis* **1**, 117–130.
- Montesano, R., Orci, L. & Vassalli, P. (1983) *J. Cell. Biol.* **97**, 1648–1652.
- Grant, D. S., Tashiro, K., Segui-Real, B., Yamada, Y., Martin, G. R. & Kleinman, H. K. (1989) *Cell* **58**, 933–943.
- Basilico, C. & Moscatelli, D. (1992) *Adv. Cancer. Res.* **59**, 115–165.
- Ziche, M., Maglione, D., Ribatti, D., Morbidelli, L., Lago, C. T., Battisti, M., Paoletti, I., Barra, A., Tucci, M., Parise, G., et al. (1997) *Lab. Invest.* **76**, 517–531.
- Szebenyi, G. & Fallon, J. F. (1999) *Int. Rev. Cytol.* **185**, 45–106.
- Seghezzi, G., Patel, S., Ren, C. J., Gualandris, A., Pintucci, G., Robbins, E. S., Shapiro, R. L., Galloway, A. C., Rifkin, D. B. & Mignatti, P. (1998) *J. Cell. Biol.* **141**, 1659–1673.
- Mima, T., Ueno, H., Fischman, D. A., Williams, L. T. & Mikawa, T. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 467–471.
- Peters, K., Werner, S., Liao, X., Wert, S., Whitsett, J. & Williams, L. (1994) *EMBO J.* **13**, 3296–3301.
- Soker, S., Takashima, S., Miao, H. Q., Neufeld, G. & Klagsbrun, M. (1998) *Cell* **92**, 735–745.
- Soldi, R., Mitola, S., Strasly, S., Defilippi, P., Tarone, G. & Bussolino, F. (1999) *EMBO J.* **18**, 882–892.
- Johnson, R. S., Spiegelman, B. M. & Papaioannou, V. E. (1992) *Cell* **71**, 577–586.
- Wang, Z.-Q., Ovitt, C., Gregoriadis, A. E., Möhle-Steinlein, U., Rüther, U. & Wagner, E. F. (1992) *Nature (London)* **360**, 742–745.
- Saez, E., Rutemberg, S. E., Mueller, E., Oppenheim, H., Smoluk, J., Yuspa, S. H. & Spiegelman, B. M. (1995) *Cell* **82**, 721–732.